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ABSTRACT

S-nitrosation is the covalent attachment of nitric oxide (NO) moiety to cysteine thiol side
chain. This reversible modification represents an important mechanism of posttranslational regulation for a large number of proteins. In the cellular environment, Snitrosoglutathione (GSNO) can transfer its NO group to reactive cysteine residues within
proteins via transnitrosation reactions. Similarly, S-nitrosated protein can transfer its NO
moiety to reduced glutathione (GSH). Due to the existence of this equilibrium, the GSNO
metabolizing enzyme GSNO reductase (GSNOR) indirectly drives protein de-nitrosation.
To date, aberrant GSNOR activity has been implicated in a large spectrum of human
diseases. In this dissertation, we report the synthesis and characterization of Oaminobenzoyl-S-nitrosoglutathione (OAbz-GSNO), a novel fluorogenic substrate for
GSNOR. OAbz-GSNO reduction mediated by GSNOR results in significant increases in
fluorescence; and this increase in fluorescence is attenuated by GSNOR inhibitor
treatment. In addition, OAbz-GSNO is cell membrane permeable and can be used to
monitor endogenous GSNOR activity in cultured cells. Overall, our work demonstrates
that OAbz-GSNO is a useful tool for assessing GSNOR activity, both in vitro and in
cells. Site-directed mutagenesis and kinetic studies conducted using recombinant GSNOR
suggest acetylation of Lys101 negatively affects enzyme activity; while computational
simulations uncovered a putative allosteric GSNO binding site. We have experimental
evidence supporting our model that GSNO binding to this allosteric site enhances
GSNOR activity. Both lysine acetylation and allosteric substrate binding represent
potential mechanisms involved in the post-translation regulation of GSNOR activity.
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Neutral sphingomyelinase II (NSMase II) is a mediator of cellular stress response.
It catalyzes the hydrolysis of plasma membrane sphingomyelin to generate bioactive
ceramide and phosphocholine. This project looks into whether chronic cortisol exposure
(as a stressor) affects NSMase II expression/activity. Experimental results demonstrate
exposure to cortisol leads to increased cell size, but NSMase II expression and activity
are unaffected. However, NSMase II over-expressing cells appear to have less cholesterol
in the plasma membrane. Since cholesterol is important for the formation of lipid rafts,
these finding suggest that in addition to ceramide generation, modulation of plasma
membrane cholesterol content may represent an alternative mechanism by which
NSMase II exerts its biological effects.
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CHAPTER 1
General Introduction

1

1.1 Nitric Oxide
Nitric oxide (NO) is a diatomic free radical gasotransmitter. In the 1980s, multiple
research groups independently identified NO as the endothelium derived relaxing factor
responsible for eliciting vascular smooth muscle relaxation [1-4]. Since then, the field of
NO biochemistry has expanded significantly and NO is now a well-established signaling
molecule known to affect a vast number of physiological processes. For instance, NO is
involved in the control of vascular tone [5-7] and blood pressure [8, 9]; promotes
angiogenesis [10]; and mediates neurotransmission [11, 12], immune response [13, 14],
as well as wound healing [15].
1.1.1 NO Synthases
Endogenous NO is enzymatically synthesized in mammalian tissues by 3 isoforms of
nitric oxide synthase (NOS; EC 1.14.13.39). The isoforms have been named neuronal
NOS (nNOS, NOS 1), inducible NOS (iNOS, NOS 2) and endothelial NOS (eNOS, NOS
3) based on their tissue of constitutive expression or basal level of activity. All NOS
isoforms function as homodimers and catalyze the oxidation of L-arginine to L-citrulline
and NO [16]. Molecular oxygen and reduced nicotinamide adenine dinucleotide
phosphate (NADPH) are co-substrates for this reaction. The overall reaction utilizes 2
mol of O2 and 1.5 mol of NADPH for every mol of NO produced [17, 18]. In addition to
substrates, NOS catalyzed NO production requires a number of cofactors/coenzymes,
including

flavin

adenine

dinucleotide

(FAD),

flavin

mononucleotide

(FMN),

tetrahydrobiopterin (BH4) and calmodulin [18].
nNOS is constitutively expressed in the neurons of the central and peripheral
nervous system, as well as epithelial cells of various organs [19, 20]. Its activity is
2

regulated by intracellular Ca2+ levels through calmodulin binding. nNOS derived NO
mediates synaptic plasticity, which affects complex physiological functions such as
neurogenesis, learning and memory formation [21, 22]. nNOS is also involved in the
central regulation of blood pressure [23, 24]. iNOS expression is usually induced by
agents such as bacterial lipopolysaccharide and cytokines. Once expressed, iNOS
produces large amounts of NO and its activity is not affected by Ca2+. In macrophages,
NO produced by iNOS contributes to host immune defense by exerting cytotoxic effects
on pathogens [14, 19]. eNOS is mainly expressed in endothelial cells and its activity is
regulated by a number of factors, including intracellular Ca2+ concentration and fluid
shear stress [25]. NO produced by endothelial cells results in vasorelaxation; and protects
blood vessels from thrombosis by inhibiting platelet aggregation and adhesion [26, 27].
1.1.2 Mechanisms of NO Signaling
Multiple mechanisms have been identified for NO-mediated signaling (Figure 1.1.2-1).
Canonical signaling involves NO activating soluble guanylate cyclase (sGC) by binding
to its heme iron [28]. Once activated, sGC converts guanosine triphosphate (GTP) to
cyclic guanosine monophosphate (cGMP). Subsequent down-stream effects are mediated
by cGMP-dependent protein kinases [29]. Within the mitochondria, NO competes with
O2 for binding to cytochrome c oxidase (CcO), the terminal enzyme of the electron
transport chain [30]. NO binding inhibits CcO. This inhibition is reversible and can
initiate biochemical events such as reactive oxygen species generation and AMP-kinase
activation [31]. NO can also signal through covalent post-translational modifications of
target proteins. These modifications include S-nitrosation, S-glutathionylation and
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tyrosine nitration [29].

The modification most relevant to this dissertation is S-

nitrosation, which is discussed in detail in the next section.

Figure 1.1.2-1 Overview of nitric oxide signaling mechanisms
Classical signaling involves nitric oxide (NO) production by nitric oxide synthase (NOS)
and the activation of soluble guanylate cyclase (sGC). Less classical signaling is based on
NO mediated inhibition of cytochrome c oxidase (CcO) in the mitochondria. Nonclassical pathways include the formation of post-translational modifications. Image from:
Martinez-Ruiz et al. (2011). "Nitric oxide signaling: classical, less classical, and non
classical mechanisms." Free Radical Biology and Medicine 51(1): 17-29. With
permission.

4

1.2 Protein S-nitrosation
S-nitrosation refers to the covalent attachment of NO derived nitroso group to a cysteine
thiol, which results in the formation of S-nitrosothiol (SNO). This modification is also
commonly known as S-nitrosylation. Chemically, the term ‘nitrosation’ describes the
addition of nitrosonium cation (NO+) to a nucleophilic group such as thiolate; whereas
‘nitrosylation’ refers to direct addition of NO to a reactant [32]. However, when the
mechanism of SNO formation is unknown or ambiguous, questions arise as to which term
should be used. Some researchers have adopted ‘S-nitrosylation’ as a general biological
term to describe the formation of SNO species regardless of mechanism (analogous to
phosphorylation or acetylation) [33], while others feel this analogy is unwarranted since
‘nitrosylation’ carries mechanistic implications and NO alone cannot react with thiols or
thiolates under physiological conditions [32]. In this dissertation, the term ‘S-nitrosation’
will be used to describe this thiol modification and to highlight the involvement of NO+.
Cysteine residues within proteins can be modified by S-nitrosation. This posttranslational modification is reversible and constitutes an important mechanism by which
NO exerts its biological effects (Figure 1.1.2-1) [29]. Over the years, there is increasing
research evidence suggesting that S-nitrosation participates in both normal physiology
and in the pathogenesis for a large spectrum of human diseases [34]. Aberrant protein Snitrosation typically involves hypo- or hyper-S-nitrosation of specific targets. This could
result from changes in the expression, localization, and/or activity of enzymes such as
NOS, which generates NO from L-arginine, and S-nitrosoglutathione reductase
(GSNOR), which promotes protein de-nitrosation by metabolizing the transnitrosating
agent S-nitrosoglutathione (GSNO).

5

Evidence to date indicates that unlike other post-translational modifications, Snitrosation of proteins is not directly catalyzed by enzymes. Instead, signaling specificity
is largely dictated by the chemical reactivity between the nitrosating agent and target
cysteine thiol [35]. Particular protein microenvironments lead to increased reactivity for
certain cysteine residues, thus favouring their modification. Several attempts have been
made to describe a putative “nitrosation motif” [36-38]. However, since S-nitrosation
could occur via multiple mechanisms [39, 40], which are still not fully understood, the
existence of a single consensus motif seems unlikely.
As previously mentioned, NO alone does not react with thiols or thiolates under
physiological conditions. For S-nitrosation to occur, NO needs to be first oxidized to
higher oxides of nitrogen such as nitrogen dioxide (NO2) or dinitrogen trioxide (N2O3).
Of the potential S-nitrosating species, N2O3 could react with thiols directly according to
Equation 1.2-1. However, questions have been raised regarding the slow kinetics of
initial NO oxidation under physiological NO and O2 concentrations [41-43].
(1.2-1)

RS- + N2O3  RSNO + NO2-

NOS activation effectively increases local NO concentrations, potentially favoring the
generation of S-nitrosating species. In this context, co-localization or direct interaction
with active NOS can positively influence S-nitrosation [44, 45]. Accelerated NO
oxidation by O2 has also been reported in hydrophobic compartments such as biological
membranes [46], further implicating the importance of subcellular compartmentalization
in controlling the occurrence and specificity of S-nitrosation.
An alternative mechanism proposed for SNO formation involves NO reacting
with a reduced thiol to form a radical intermediate. Then, in the presence of an electron
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acceptor (such as O2 ) SNO and superoxide are formed [47]. In 1996, Schmidt and
colleagues attempted to measure NOS-produced NO radical directly (rather than nitrate
or nitrite) and reported that NOS did not yield detectable NO unless superoxide
dismutase (SOD) was also present. Based on experimental findings, this group concluded
NOS activity produces NO- as an NO precursor, which is acted upon by SOD to generate
NO. In addition, when both SOD and GSH are present, the formation of GSNO was
detected [48]. These observations provided strong evidence for enzyme mediated SNO
formation.
Proteins can become S-nitrosated via transnitrosation. These reactions are fully
reversible and often involve low molecular weight SNO such as GSNO (Equation 1.2-2).
(1.2-2)

RS- + GSNO ↔ RSNO + GS-

Interestingly, ferric cytochrome c can promote GSNO formation; the proposed
mechanism involves initial weak binding between GSH and cytochrome c, followed by
reaction with NO to generate GSNO and ferrous cytochrome c [49]. This increase in
GSNO levels in turn promotes S-nitrosation of proteins [50]. In addition to cytochrome c,
dinitrosyl iron complexes have also been shown to enhance S-nitrosation of proteins
through transnitrosation [51, 52].
More recently, de-nitrosation pathways have emerged as another important
regulatory mechanism for signaling through S-nitrosation [53]. Due to the reversible
nature of transnitrosation, increases in cellular glutathione (GSH), as well as decreased
levels of GSNO, both contribute to protein de-nitrosation. A number of enzyme systems
(including GSNOR [54], superoxide dismutase [55], glutathione peroxidase [56],
thioredoxin [57], and carbonyl reductase 1 [58]) have been proposed to be involved in
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GSNO metabolism in humans. Of these enzymes, only GSNOR and carbonyl reductase 1
are capable of irreversibly removing the NO equivalents stored in GSNO, while kinetic
comparisons suggest GSNOR is the most efficient GSNO-metabolizing enzyme [59].
1.3 S-nitrosoglutathione Reductase
1.3.1 From Class III Alcohol Dehydrogenase to S-nitrosoglutathione Reductase
Mammalian alcohol dehydrogenase (ADH) belongs to the protein superfamily of medium
chain dehydrogenases / reductases [60] and consists of at least six known classes based
on primary structure and function [61]. ADH is the major enzyme system responsible for
ethanol metabolism (Reaction 1.3.1-1) and can also catalyze the oxidation of other
primary and secondary alcohols using nicotinamide adenine dinucleotide (NAD+) as the
co-factor.

Reaction 1.3.1-1 ADH catalyzed ethanol oxidation, forming acetaldehyde as the product.

Class III alcohol dehydrogenase (ADH III) was first isolated and purified to
homogeneity from the human liver in the 1980s [62, 63]. Early studies revealed that even
though ADH III resembles previously discovered ADH isozymes in terms of molecular
weight, metal ion binding, and optimal pH for catalytic activity, it differs remarkably
from other known ADH members by exhibiting very poor activity towards ethanol, with
an apparent Km of more than 2 M [62, 63]. Instead, ADH III prefers long chain primary
alcohols and aldehydes as substrates [63, 64]. In 1989, Koivusalo et al. reported evidence
that ADH III is actually homologous to the ubiquitous cytosolic enzyme formaldehyde
8

dehydrogenase which catalyzes the oxidation of S-hydroxymethylglutathione (HMGSH)
to S-formylglutathione (Reaction 1.3.1-2) [65, 66]. The adduct HMGSH is formed
spontaneously between formaldehyde and glutathione. By metabolizing HMGSH, ADHIII was noted as an important component in formaldehyde detoxification [67].
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Reaction 1.3.1-2 Formaldehyde is a highly toxic metabolite. In the presence of GSH, it
forms the adduct HMGSH, which in turn is converted to S-formylglutathione by ADH III
using NAD+ as the cofactor.
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Later in 1998, Jensen and colleagues discovered that in addition to activity
towards HMGSH, ADH III can efficiently catalyze the NADH-dependent reduction of
GSNO [54]. As a result, this enzyme is sometimes referred to as GSNO reductase
(GSNOR). Since GSNO is considered to be an endogenous mediator of NO signaling,
this enzyme with GSNO reductase activity rapidly caught the attention of researchers in
the NO signaling field.
Many

different

nomenclatures

(including

ADH

III,

chi-chi

alcohol

dehydrogenase, glutathione-dependent formaldehyde dehydrogenase, and GSNO
reductase) have been used in literature to describe this enzyme. In all subsequent sections
of this dissertation, the name GSNOR will be consistently used to refer to this enzyme.
1.3.2 Regulation of GSNOR Gene Expression
In humans, there are 7 identified ADH genes located in a cluster on chromosome 4q.
GSNOR is encoded by the gene ADH5, which consists of 9 exons. The 5’ untranslated
region of ADH5 is GC rich and lacks a TATA or CAAT box; both of which are
characteristics of housekeeping genes with ubiquitous expression [68]. Several research
groups have looked into the regulation of ADH5 expression. A study by Kwon et al.
revealed two specificity protein 1 (Sp1) binding sites critical for transcription initiation,
while competitive binding by Sp3 or Sp4 represses ADH5 expression [69]. Interestingly,
high levels of GSNO can decrease/inhibit Sp3 binding on the cystic fibrosis
transmembrane conductance regulatory gene (CFTR) [70]. If GSNO also negatively
affects Sp3 binding on ADH5, this could represent a regulatory feedback loop for
GSNOR such that when GSNO concentration is high, Sp3 binding is inhibited to favour
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Sp1 binding and ADH5 transcription; which in turn leads to increased GSNOR
expression and increased GSNO metabolism until homeostasis is restored.
In addition to Sp binding sites, ADH5 also contains an up-stream open reading
frame with two possible AUG start codons. These up-stream open reading frames are an
unusual feature in mammalian mRNAs and have been postulated to play a regulatory role
as mutations at one or both of these up-stream AUG codons led to an increase in ADH5
gene expression [71].
1.3.3 GSNOR Protein Structure
Crystal structure of human GSNOR shows that it is a homodimer with 40 kDa subunits
(Figure 1.3.3-1). Each subunit contains a catalytic domain and a coenzyme binding
domain. The catalytic domain is completely solvent exposed and displays a semi-open
conformation. This conformation provides the structural basis for GSNOR’s ability to
accommodate larger substrates such as HMGSH and GSNO [72]. Mutagenesis studies
suggest that the positively charged Arg115 is critical for HMGSH binding. When this
residue is changed to Asp, catalytic efficiency for HMGSH oxidation decreases
significantly [73]. In addition to Arg115, HMGSH also interacts with the highly
conserved Thr47, Asp56 and Glu58 [74]. Whether the same residues facilitate the binding
of GSNO is currently unknown.
Similar to all other members of the ADH family, GSNOR is a zinc containing
enzyme. Each subunit contains one catalytic zinc, as well as one structural zinc (Figure
1.3.3-1). The catalytic zinc is located within the active site and acts as a Lewis acid
during catalysis; while the structural zinc is critical for the maintenance of proper protein
structure.
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A number of studies have looked at the coordination environment of the active
site zinc [74-77]. In the apoenzyme, the active site zinc is coordinated by Cys45, His67,
Cys174 and a water molecule. Upon coenzyme binding, the active site zinc is displaced
towards Glu68. This displacement decreases interaction with the solvent water molecule
and has been postulated to facilitate ligand exchange at the active site [76].
The structural zinc is coordinated by four closely spaced cysteine residues
(Cys97, Cys100, Cys103 and Cys111). This coordination pattern is highly conserved for
all classes of ADH [78]. Even though the structural zinc does not directly participate in
catalysis, it is still a critical feature and mutating any one of these four cysteine residues
results in inactive and unstable enzyme [79]. Although the sensitivity of these cysteine
residues towards oxidation has not yet being evaluated, it is feasible that the peptide
microenvironment contributes to the maintenance of proper oxidation state.
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Figure 1.3.3-1 GSNOR protein structure
Left: dimeric structure of GSNOR with the monomers shown in green and yellow. Right:
close up view of the active site. Image from: Staab et al. (2008). "Medium- and shortchain dehydrogenase/reductase gene and protein families: Dual functions of alcohol
dehydrogenase 3: implications with focus on formaldehyde dehydrogenase and Snitrosoglutathione reductase activities." Cellular and Molecular Life Sciences 65(24):
3950-3960. With permission.
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1.3.4 Functions of GSNOR
GSNOR is highly conserved in both prokaryotic and eukaryotic organisms [80-83], and is
ubiquitously expressed in all human tissues studied [84, 85]. This universal pattern of
expression suggests that GSNOR likely performs important cellular functions. Over the
years, numerous studies have presented evidence that GSNOR participates in a number of
pathways, ranging from first-pass ethanol metabolism in the gastric lumen following
ethanol consumption [86], to ω-hydroxy fatty acid oxidation [54, 65], formaldehyde
detoxification [67, 87-89], and GSNO metabolism [54, 90-93]. Two of the better
characterized activities of GSNOR are glutathione-dependent formaldehyde oxidation
(Reaction 1.3.1-2), and NADH-dependent GSNO reduction (Figure 1.3.4-1).
The glutathione-dependent formaldehyde dehydrogenase (FDH) activity is an
important mechanism for the elimination of formaldehyde, which is a classified
carcinogen due to its high reactivity towards DNA and proteins [94-96]. Sources of
cellular formaldehyde include both endogenous metabolism and environmental exposure
[97-100]. Under physiological conditions, formaldehyde readily reacts with glutathione
(GSH) to form HMGSH [87], which is in turn converted to S-formylglutathione by
GSNOR, using NAD+ as the cofactor. Finally, S-formylglutathione is broken down to
glutathione and the less reactive formate by S-formylglutathione hydrolase [101, 102].
Immunocytochemical studies demonstrate that GSNOR is localized to the cytoplasm as
well as over condensed chromatin in the nucleus [103]. The nuclear localization of
GSNOR supports its role in protecting DNA from formaldehyde toxicity.
In addition to GSNOR, there are enzymes (ALDH1A1 and ALDH2 in humans)
from the aldehyde dehydrogenase superfamily that can metabolize free formaldehyde
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directly [104-106]. However, their Km values for formaldehyde are much greater than the
one GSNOR shows with HMGSH, suggesting that GSNOR is the more efficient enzyme
for formaldehyde detoxification [65, 91, 106].
The functional aspect of GSNOR most relevant to this dissertation is its GSNO
reductase activity. In 1998, Jensen and co-workers reported that GSNO is a substrate for
GSNOR and this reduction reaction uses one mol of NADH per mol of GSNO
metabolized [54]. Product analyses performed by the same research group suggest the
major stable product is glutathione sulfinamide. However, when an excess of GSH was
included in the reaction mix in vitro, the formation of GSSG and hydroxylamine
appeared to be favoured (Figure 1.3.4-1) [54]. A few years later, Liu et al. reported the
purification of GSNOR from Escherichia coli, Saccharomyces cerevisiae and mouse
macrophages and demonstrated that GSNOR is highly specific towards GSNO with no
activity observed towards S-nitrosocysteine and S-nitrosohomocysteine [107].
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Figure 1.3.4-1 Proposed reaction scheme for GSNOR catalyzed GSNO degradation
Image from: Jensen et al. (1998). "S-nitrosoglutathione is a substrate for rat alcohol
dehydrogenase class III isoenzyme." Biochemical Journal 331 (Pt 2): 659-668. With
permission.
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Under physiological redox conditions, the ratio of free NADH / NAD+ is usually
low [108]. This is considered unfavorable for reductive pathways which require NADH
and implies that the reductase activity of GSNOR might depend on cofactor availability.
Various factors could trigger an increase in cellular NADH levels, such as ADH mediated
ethanol metabolism [109] and the inhibition of NADH dehydrogenase [91]. However,
whether these events directly contribute to the activation of GSNOR reductase activity
remain unclear. A more recent study by Staab et al. suggests that NADH produced by
GSNOR catalyzed oxidation reactions remain bound to the enzyme and could promote
GSNO reduction via direct cofactor recycling [110]. In addition, steady state kinetics of
human GSNOR show that the kcat / Km for GSNO reduction is approximately twice the
kcat / Km for HMGSH oxidation, and the reduction reaction is essentially irreversible as
neither glutathione sulfinamide nor GSSG works as substrate or inhibitor for GSNOR
[111]. With these factors considered, it becomes feasible to drive the reaction in the
reductive direction despite unfavourable NADH / NAD+ ratios, lending further support
that GSNOR is a physiologically relevant enzyme for GSNO metabolism.
Furthermore, GSNOR deficient mice (GSNOR

-/-

) has been shown to exhibit

substantial increases in protein S-nitrosation [112]. Since it is generally accepted that in
the cellular environment, GSNO is in equilibrium with a subset of S-nitrosated proteins
via reversible transnitrosation (Figure 1.3.4-2), the observation that GSNOR deficient
mice experience increased levels of S-nitrosation places GSNOR in a crucial role in
maintaining SNO homeostasis via its GSNO reductase activity.
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Figure 1.3.4-2 Regulation of SNO homeostasis by GSNOR
(a) GSNO is in equilibrium with a subset of S-nitrosated proteins. By metabolizing
GSNO, GSNOR removes NO equivalents from the bioactive NO pool; and indirectly
promotes protein de-nitrosation. (b) GSNOR knockout mice exhibit increased SNO
levels with physiological consequences. (c) GSNOR expression and activity are
associated with human asthma. Image from: Foster et al. (2009). "Protein S-nitrosylation
in health and disease: a current perspective." Trends in Molecular Medicine 15(9): 391404. With permission.
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1.3.5 GSNOR’s Involvement in Physiology
In 2004, Liu et al. generated GSNOR deficient mice (GSNOR

-/-

) using homologous

recombination. These animals exhibit increased level of whole cell S-nitrosation,
increased level of SNO in their red blood cells, and are more susceptible to endotoxic or
bacterial challenge [112]; suggesting immunity could be affected by SNO and GSNOR
activity. A number of subsequent studies using this animal model offered additional
insights into GSNOR’s involvement in physiology. Lima et al. observed an increase in
myocardial capillary density and cardio-protective characteristics in GSNOR deficient
animals. These findings are further supported by another study which demonstrated that
GSNOR -/- mice have preserved cardiac function after myocardial infarction [113].
In pulmonary physiology, GSNO has been identified as a long-lived and potent
relaxant of human airways [114]. This endogenous bronchodilator appears to be depleted
in the airway linings of individuals with asthma, which is a chronic disease characterized
by airway inflammation and hyper-responsiveness [115]. Interestingly, following an
allergen challenge, GSNOR null mice have substantially higher levels of SNO in the
lungs than their wild-type counterparts and are protected from airway hyper-responsivity
[116]. These observations led researchers to propose a novel therapeutic approach of
targeted GSNOR inhibition to restore SNO levels and alleviate asthma symptoms. In
2013, Ferrini et al. reported intranasal administration of the GSNOR inhibitor SPL334
reduces airway hyper-reactivity, inflammation, and mucus production in a mouse model
of allergic asthma [117]. A year later, Blonder et al.

published findings showing

treatment with the GSNOR inhibitor N6022 restores GSNO levels and leads to
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bronchodilation, as well as reduced inflammation [118]. N6022 is currently undergoing
clinical evaluation for the treatment of inflammatory lung disease.
GSNOR and its ability to modulate SNO levels also play a role in cystic fibrosis
(CF). Development of CF is attributed to mutations in the CFTR gene. The common
ΔF508 mutation causes protein misfolding, in which case the protein fails to mature and
is degraded in the endoplasmic reticulum (ER) [119]. A number of studies have
demonstrated that GSNO can increase CFTR maturation and partially restore the function
of ΔF508 CFTR by directing it to the plasma membrane [120-122]. Most recently, Zaman
et al. reported an inverse relationship between GSNOR activity and the expression and
maturation of CFTR [123], with the implication that pharmacological inhibition of
GSNOR could potentially benefit patients with CF.
Since increasing GSNO levels appear to have beneficial consequences in a
number of cardiovascular and pulmonary conditions, the synthesis and characterization of
small molecule GSNOR inhibitors have gained attention. [124-127]. However, this
promising therapeutic approach is complicated by findings which suggest GSNOR
activity is important for protecting cells from nitrosative stress. For example, the DNA
repair protein O(6)-alkylguanine-DNA alkyltransferase confers protection against
alkylation induced mutagenesis in the liver; but GSNOR deficiency results in Snitrosation and proteosomal degradation of this key repair protein under inflammatory
conditions [128-130]. In this context, GSNOR deficient mice are more susceptible to both
spontaneous and carcinogen-induced hepatocellular carcinoma. Similarly, decreased
GSNOR activity is associated with human lung cancer via Ras S-nitrosation and

20

activation [131]. These oncogenic potentials should be taken into consideration when
evaluating therapies involving pharmacological GSNOR inhibition.
1.4 Neutral Sphingomyelinase II
1.4.1 A Brief History of Discovery
Sphingomyelinase (EC.3.1.4.12) is a family of enzymes which catalyzes the hydrolysis of
the sphingolipid sphingomyelin (SM) to form bioactive ceramide and phosphocholine.
Ceramide, along with its downstream metabolites, are important second messenger
molecules capable of modulating a variety of cellular events, such as cell cycle arrest,
differentiation, inflammation and apoptosis [132-134].
The family of sphingomyelinase enzymes can be further divided into three groups
based on their distinct catalytic pH optimum. Acid sphingomyelinase is responsible for
the catabolism of SM within lysosomes and deficiency of this enzyme leads to the human
Niemann-Pick disease [135, 136]. More recently, acid sphingomyelinase has been
reported to contribute to stress induced ceramide generation and subsequent pro-apoptotic
signaling pathways [137-142]. On the other hand, alkaline sphingomyelinase is found in
the intestinal tract, bile and liver; and participates in sphingomyelin digestion [143, 144].
Findings by Zhang et al. also suggest the potential involvement of alkaline
sphingomyelinase in regulating mucosal growth, as well as alkaline phosphatase function
[145].
Neutral magnesium-dependent sphingomyelinase activity was first reported by
Scheider and Kennedy in 1967 [136]. Since then, several mammalian forms have been
identified and studied. Neutral sphingomyelinase I was cloned based on remote sequence
similarity to known bacterial sphingomyelinases in 1998 [146]. A year later, results from
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overexpression and radiolabeling experiments suggest that this integral membrane protein
does not hydrolyze sphingomyelin in cultured cells; and instead functions as a lysoplatelet activating factor (lysoPAF) phospholipase C [147]. However, studies involving
neutral

sphingomyelinase

I knockout

mouse

do

not

support

the

proposed

lysophospholipase C activity [148]. To date, the physiological roles of mammalian
neutral sphingomyelinase I remain elusive.
In 2000, Hofmann and colleagues reported the identification of mammalian
neutral sphingomyelinase II (NSMase II) based on remote similarity to bacterial
sphingomyelinases using a bioinformatics-based gene discovery approach coupled with
phylogenetic analysis [149]. This membrane protein consists of 655 amino acid residues
and has an overall predicted molecular weight of 71 kDa. Biochemical studies of
NSMase II suggest that it is magnesium-dependent and can be activated by unsaturated
fatty acids as well as anionic phospholipids, such as phosphatidylserine [149, 150].
Unlike neutral sphingomyelinase I, NSMase II exhibits genuine sphingomyelinase
activity both in vitro and in vivo with overexpression of this enzyme resulting in
accelerated SM catabolism and an increase in ceramide levels [150]. As a result, NSMase
II is viewed by many researchers as a prime candidate involved in ceramide generation
and signaling.
More recently, neutral sphingomyelinase III was identified using peptide
sequence from purified bovine sphingomyelinases [151]. A study by Cororan et al.
suggests this 97 kDa protein may be linked to tumorigenesis and cellular stress response
[152]. Independent confirmation of its activity and functional roles are yet to be reported.
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1.4.2 NSMase II Protein Structure
Crystal structures of mammalian neutral sphingomyelinases have not yet been reported.
Therefore, the currently accepted domain structures are based on a combination of amino
acid sequence analysis, comparison to known bacterial neutral sphingomyelinase
structures

and

various

biochemical

studies.

Among

the

different

neutral

sphingomyelinase enzymes reported, structural homology is relatively low (Figure 1.4.21).
The proposed domain structure of NSMase II consists of two hydrophobic
segments near the N-terminus, followed by a 200 residue collagen-like triple helices and
a catalytic domain near the C-terminus (Figure 1.4.2-1) [149]. Although the two
hydrophobic segments were initially proposed to be transmembrane domains, subsequent
analysis of NSMase II membrane topology suggested that these segments do not actually
span the entire membrane [153]. Two discrete anionic phospholipid (APL) binding
domains were identified near the N-terminus which allow NSMase II to interact
specifically with certain APLs including phosphatidylserine and phosphatidic acid [154].
The two APL binding domains partially overlap with the hydrophobic segments and
additional mutagenesis studies reveal that Arg33, Arg45 and Arg48 are essential for
interaction with APL in the first domain while Arg92 and Arg93 are critical for the
second domain [154]. NSMase II can also be palmitoylated in two cysteine clusters via
thioester bonds. This modification appears to be important for protein stability, as well as
protein localization with palmitoylation deficient mutants showing rapid degradation and
reduced membrane association [155].
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Figure 1.4.2-1 Proposed domain structures of human neutral sphingomyelinases
Neutral sphingomyelinase I (accession number O60906), neutral sphingomyelinase II
(accession number Q9NY59) and neutral sphingomyelinase III (accession number
NP060421). Image from Wu et al. (2010). "Mammalian Neutral Sphingomyelinases:
Regulation and Roles in Cell Signaling Responses." Neuromolecular Medicine 12(4):
320-330. With permission.
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1.4.3 Subcellular Localization of NSMase II
The subcellular localization of NSMase II has been reported mainly in two organelles.
Hofmann et al. observed localization predominantly at the Golgi in several cell lines
derived from the brain [149]. In contrast, Marchesini et al. reported localization at the
plasma membrane in confluence arrested MCF7 cells [156]. This apparent discrepancy in
localization could be explained by results from subsequent studies which demonstrate
NSMase II is transported between the plasma membrane and intracellular sites [157].
Using A549 epithelial cells, Clarke et al. observed acute translocation of NSMase II to
the plasma membrane in response to tumor necrosis factor α [158]. In the same year,
Levy et al. reported preferential trafficking of NSMase II to the plasma membrane under
conditions of oxidative stress. Conversely, exposure to the antioxidant glutathione leads
to nuclear localization of NSMase II, where both ceramide generation and apoptosis
appear to be attenuated [159]. Together, these findings suggest subcellular localization of
NSMase II affect its function and intracellular trafficking is one of the mechanisms
regulating its catalytic activity.
1.4.4 Physiological Roles of NSMase II
Since its discovery, NSMase II has been shown to participate in a large number of
physiological processes. This section will highlight some of the major biological
functions attributed to NSMase II.

Role of NSMase II in Oxidative Stress
NSMase II is an important mediator of cellular stress response, mainly through the
production of ceramide. In human airway epithelial cells (HAEC), exposure to oxidative
stressors (H2O2 and cigarette smoke) selectively induces the activation of NSMase II;
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with the resultant increase in cellular ceramide leading to HAEC apoptosis and lung
injury. This apoptotic response to oxidative stress is lost upon siRNA silencing of
NSMase II [159, 160]. In addition, NSMase II expression level is significantly higher in
lung tissues obtained from smokers with pulmonary emphysema as compared to normal
control subjects [161], suggesting an in vivo role of NSMase II in oxidative stress
induced ceramide generation and lung injury. Interestingly, another study presented
evidence that NSMase II and ceramide are critical for lung development. Poirier et al.
studied lung phenotype from fro/fro mice, which express catalytically inactive NSMase II
due to gene mutation, and noticed these animals exhibit symptoms similar to emphysema
[162]. This raises the possibility that perhaps basal levels of NSMase II activity are
required for normal lung development. More research is needed to fully understand this
enzyme’s biological function in pulmonary physiology.
In addition to pulmonary physiology, Clement et al. [163] demonstrated that
certain types of neuronal cells can adapt to chronic oxidative stress by down-regulating
NSMase activity. These cells exhibit increased intracellular cholesterol levels and are
resistant to apoptosis. Extracellular treatment of the stress resistant cells with NSMase
reverses the stress-resistant phenotype; while treating oxidative stress sensitive neuronal
cells with NSMase inhibitors made the cells more resistant to oxidative stress.

Effect of NSMase II Activity on NOS
ER stress inhibits NSMase II activity in bovine aortic endothelial cells [164]. When cells
were treated with the ER stressor palmitate or tunicamycin, reduced NSMase II activity
leads to less ceramide generation, which attenuates ceramide dependent eNOS activation
and results in decreases in NO production [165]. Similarly, siRNA mediated knock-down
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of NSMase II also results in decreased NO generation [164]. This reduced bioavailability
of NO promotes the dominance of vasoconstriction over vasodilation. As a result,
decreased NSMase II activity is proposed to be a contributing factor in the induction of
endothelial dysfunction.
In C6 rat
lipopolysaccharide

glioma cells, inhibition of NSMase II activity prevents
induced

iNOS

expression,

whereas

inhibition

of

acid

sphingomyelinase activity or ceramide de novo synthesis have no effect; suggesting
ceramide generated by NSMase II is critical in the regulation of iNOS expression [166].
In agreement with this line of evidence, treatment with GW4869, a specific NSMase
inhibitor, decreases iNOS expression in cultured human retinal pigment epithelial cells.
This reduces nitrosative stress experienced by these cells and protects them from ER
stress-induced apoptosis [167]. Overall, it appears that NSMase II catalyzed ceramide
generation enhances NOS expression and activity.

Role of NSMase II in Inflammation
Long-term as well as acute stimulation with the pro-inflammatory cytokine tumour
necrosis factor alpha (TNF-α) activates NSMase II in cultured cells, leading to rapid
sphingomyelin hydrolysis and ceramide generation [165, 168, 169]. Clark et al. observed
that exposure to TNF-α results in the translocation of NSMase II to the plasma membrane
in a time- and dose-dependent manner; and this translocation and activation are
dependent on p38 MAPK [158] and protein kinase C-delta [170]. In 2012, Barth and
colleagues reported that TNF-α activates NSMase II in both neurons and non-neuron
cells,

causing

ceramide accumulation,

ROS

formation and

apoptosis

[171].

Mechanistically, residues 309 to 319 of TNF-α receptor (p55) form the neutral
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sphingomyelinase activation domain (NSD) [172]. However, this domain does not
directly interact with NSMase II. Instead, NSD binds factor-associated with neutral
sphingomyelinase (FAN) [173, 174], which interacts with receptor for activated C-kinase
1 (RACK1) [175], which in turn interacts with the polycomb group protein EED [176].
EED has been identified as a direct interaction partner for NSMase II [176] and
physically couples NSMase II to the [RACK1-FAN-TNF receptor] complex allowing the
transduction of signals initiated by TNF-α. Two other inflammatory cytokines,
interleukin-1 beta [177, 178] and interferon gamma [179], can also increase NSMase II
activity. Due to its involvement in these signaling pathways, NSMase II has been
suggested as a potential drug target for inflammatory diseases [180].

Role of NSMase II in Cancer
The functional role of NSMase II in cancer initiation and progression has been under
examination with some conflicting results reported. Nucleotide sequencing in a panel of
human cancers discovered mutations in the gene encoding NSMase II in a subset of
human leukemia. These mutations appear to result in defects in NSMase II stability and
localization [181]. Another study looked at the genome-wide methylation status in
hepatocellular carcinoma and identified NSMase II as a tumour suppressor, with
overexpression leading to 50% reduction in proliferation [182]. However, NSMase II has
also been reported to promote angiogenesis [183] and metastasis in breast cancer by
regulating exosomal microRNA secretion [184]. Additional research in this area is
needed before we can determine whether these conflicting findings are due to tissuespecific functions of NSMase II or some other unknown factors.
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A number of anti-cancer drugs have been shown to act through NSMase II. Ito et
al. observed that treatment with the chemotherapeutic drug daunorubicin increases
NSMase II mRNA and protein levels in MCF7 cells. This up-regulation of NSMase II
facilitates daunorubicin-induced cell death via ceramide generation [185]. In
oligodendrocytes, NSMase II over-expression leads to increased ceramide generation and
enhances apoptosis induced by staurosporine or C(2) ceramide [186]. In addition,
protopanaxadiol, from the root extract of Panax ginseng, exerts cytotoxic effects against 5
different cancer cell lines through NSMase II activation and disruption of membrane lipid
rafts [187].
1.4.5 Regulation of NSMase II
NSMase II is a redox sensitive enzyme and the antioxidant GSH inhibits its upregulation
[159, 188]. In MCF7 cells, pre-treatment with GSH prevents diamide (thiol depleting
agent) induced NSMase activation [189]. Similarly, treatment with GSH also protects
HAEC from oxidative stress induced ceramide generation and apoptosis [159, 160]. It is
interesting to note that human NSMase II has 23 cysteine residues. Whether these
residues participate in the redox regulation of NSMase II activity, via modifications such
as S-nitrosation, remain under investigation.
All-trans retinoic acid (ATRA) causes G0/G1 growth arrest in many cell types.
Using MCF7 cells as a model system, Clarke et al. demonstrated that ATRA induced
growth arrest is mediated by increased NSMase II activity and cellular ceramide levels
[190]. This increase in NSMase II activity was later found to be mostly due to enhanced
transcription. Ito et al. [191] uncovered 3 Sp1 sites within the 5’ promoter region of
NSMase II and presented evidence that ATRA treatment activates PKCδ which
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phosphorylates Sp1. The phosphorylated Sp1 transcription factor then binds to the
NSMase II promoter, resulting in increased level of transcription.
More recently, Filosto and colleagues reported that NSMase II is a
phosphoprotein with phosphorylation occurring exclusively at serine residues [192]. This
phosphorylation event was proposed to occur downstream of p38 MAPK and PKC [192].
In human airway epithelial cells, exposure to oxidative stress enhances NSMase II
phosphorylation, which results in increased activity [192, 193]. The phosphatase
calcineurin has also been reported to bind directly to NSMase II; and when the binding
site was mutated away, NSMase II would exhibit constitutively elevated phosphorylation
and activity [192]. Subsequent publication by the same research group identified five
serine residues which are phosphorylated. Three of these residues (Ser289, Ser292 and
Ser299) are positioned near the catalytic domain, while the other two (Ser173 and
Ser208) are adjacent to the calcineurin binding site [193]. Overall, phosphorylation of
these five serine residues appears to play a critical role in NSMase II activation under
oxidative stress. In addition, NSMase II protein stability could also be regulated posttranslationally by phosphorylation; with phosphorylation of Ser208 leading to increased
stability [193].
In summary, NSMase II mediated sphingomyelin hydrolysis and ceramide
generation has emerged as an important component in a number of signaling pathways.
And as such, aberrant activation or inhibition of NSMase II could potentially contribute
to the development of pathological conditions.
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CHAPTER 2
O-aminobenzoyl-S-nitrosoglutathione is a Novel Fluorogenic Substrate for
S-nitrosoglutathione Reductase
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2.1 Introduction
Class III alcohol dehydrogenase (ADH III) was first isolated and purified from the human
liver in 1984 by Wagner et al. [63]. Early studies have shown that this enzyme exhibits
very poor activity towards ethanol, and instead, prefers long chain primary alcohols and
aldehydes as substrates [63, 64]. A few years later, Koivusalo et al. provided strong
evidence that ADH III is identical to formaldehyde dehydrogenase which catalyzes the
NAD+-dependent oxidation of hydroxymethylglutathione (HMGSH) [65]. In 1998,
Jensen and colleagues discovered that in addition to formaldehyde dehydrogenase
activity, ADH III can specifically and efficiently reduce S-nitrosoglutathione (GSNO)
using NADH as the cofactor [54]. As a result of this enzymatic activity, ADH III was
renamed GSNO reductase (GSNOR) by researchers in the S-nitrosothiol (SNO) signaling
field.
SNO is the collective term used to describe molecules containing an NO group
covalently attached to the sulfur atom of a thiol. GSNO, the substrate for GSNOR, is an
endogenous SNO derived from glutathione, which is the most abundant cellular thiol.
GSNO contributes to nitric oxide signaling via transnitrosation (the transfer of its NO
group to reactive cysteine residues on target proteins). Once S-nitrosated, proteins often
exhibit altered properties and/or functions. Over the years, there is increasing evidence
which suggest that dysregulation of S-nitrosation correlates with a broad range of human
pathologies [34, 194-196]. Since GSNO exists in equilibrium with S-nitrosated proteins,
many of the biological functions of GSNOR are based on its ability to metabolize GSNO
and drive protein denitrosation. This implies aberrant expression and/or activity of
GSNOR could disturb cellular SNO homeostasis and contribute to pathogenesis.
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Research has demonstrated various roles for GSNOR related to cardiovascular
and respiratory health and disease. For example, GSNOR deficient mice are protected
from experimentally induced asthma [116] and show cardio-protection with myocardial
infarction [197]. GSNOR is linked to asthmatic responsiveness in humans with single
nucleotide polymorphisms influencing responsiveness to bronchodilators [198, 199].
GSNOR also plays roles in vasculogenesis [200], bronchopulmonary dysplasia [201,
202], lung cancer [131] and cystic fibrosis [123]. The involvement of GSNOR in these
significant heart- and lung-related pathologies has made it a promising therapeutic target
for modulating intracellular SNO levels [118, 203, 204].
The conventional method for measuring GSNOR activity involves monitoring the
decrease in absorbance at 340 nm. This decrease in absorbance is due to both NADH and
GSNO consumption [54]. While this assay is easy to use, its application is limited to
purified enzyme in vitro. Currently, there are no direct and specific spectroscopic probes
to monitor GSNOR activity in cultured cell. Such probes would permit studies related to
the localization and regulation of the enzyme within organelles as well as the direct
assessment of the effectiveness of GSNOR-specific therapeutics.
In this chapter, we introduce O-aminobenzoyl-S-nitrosoglutathione (OAbzGSNO) as a fluorogenic substrate for GSNOR. The characterization of OAbz-GSNO
includes in vitro catalytic properties, cell permeability and usefulness in measuring
GSNOR activity in live, primary murine lung endothelial cells.
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2.2 Materials
DNase I (DN25), glutathione, reduced (G4251), imidazole (I0125), isatoic anhydride
(I12808), isopropyl β-D-1-thiogalactopyranoside (I6758), lysozyme (L7651), βnicotinamide adenine dinucleotide, reduced (N8129), phenylmethylsulfonyl fluoride
(7626), QAE sephadex (Q25120), sodium nitrite (S2252), sodium phosphate dibasic
(S7907), sodium phosphate monobasic (S8282) and Triton X-100 (T9284) were
purchased from Sigma-Aldrich. Glycerol (G3700) and sodium chloride (S2830) were
purchased from ACP Chemicals. Kanamycin (BP906) and Tris-HCl (BP153) were
purchased from Fisher Scientific. Dithiothreitol (100597) was purchased from MP
Biomedicals. The inhibitor N6022 was obtained from MedChem Express, Princeton, NJ.
2.3 Methods
2.3.1 S-nitrosoglutathione (GSNO) synthesis
Reduced glutathione (5 mmol) was dissolved in 8 mL of cold water and 2.5 mL of 2 M
HCl. Equal amount of sodium nitrite (5 mmol) was added and the reaction mixture was
stirred at 4°C in the dark for 40 minutes. After 40 minutes, GSNO was precipitated using
10 mL of cold acetone. Finally, the pink product was washed with cold water (5 X 1 mL)
and cold acetone (3 X 10 mL) before it was lyophilized for storage at -20°C.
2.3.2 O-aminobenzoyl GSNO synthesis
GSNO (0.15 mmol) was dissolved in 3.0 mL of 0.5 M phosphate buffer (pH 8.5). To
this, excess isatoic anhydride (0.9 mmol), which has been previously recrystallized from
isopropanol, was added and the mixture was stirred at 4°C for 24 hours. After the
insoluble salts were removed by centrifugation, the clear supernatant was applied onto a
BioRad econo-column containing 2 mL of packed QAE-Sephadex pre-equilibrated with
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distilled water. Unreacted isatoic anhydride was removed with 10 mL of wash buffer (0.1
M phosphate, pH 7.4). OAbz-GSNO, visualized as the red-orange band adhering to the
top of the column, was then eluted with wash buffer containing 1 M NaCl. 5 µl from each
of the red-orange fractions corresponding to the product was added to a fluorescence
cuvette containing 1.0 mL of phosphate buffered saline (PBS). The emission at 415 nm
was monitored (excitation at 312 nm) before and after the addition of 10 mM
dithiothreitol (DTT). Fractions which showed maximal fluorescence enhancement in the
presence of DTT were pooled and aliquoted for subsequent studies. OAbz-GSNO is
stable for at least 1 year when stored at -80°C, in the absence of repeated freeze-thaw
cycles.
2.3.3 NMR characterization
Pooled OAbz-GSNO was lyophilized and then re-dissolved in minimum volume D2O.
Spectra were collected on a Bruker 500 MHz Avance III spectrometer using a BBFO
probe. Peak assignments were based on a 1H-1H COSY45 spectrum. 1H-13C HMQC and
HMBC experiments were also performed to help determine 1H-13C correlations.
2.3.4 ADH5 sub-cloning
Human ADH5, which encodes full length GSNOR, was purchased from Origene
(SC119755) and sub-cloned into the bacterial expression vector pET28b using Cold
Fusion Cloning Kit (MJS BioLynx Inc. SYMC010A1). Cloning strategy involves direct
ligation of PCR amplified gene of interest to the linearized destination vector.
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Primers used for PCR were designed according to manufacturer’s guidelines and contain
bases complimentary to the gene of interest as well as bases complementary to the
linearized destination vector. The following primers were used for ADH5 sub-cloning:
Forward 5’– GTGCCGCGCGGCAGCCATATGGCGAACGAGGTTATCAAG –3’
Reverse 5’– GTGGTGGTGGTGGTGCTCGAGAATCTTTACAACAGTTCGAATG –3’
Prior to the ligation reaction, destination vector pET28b was linearized by digestion with
restriction enzymes NdeI and XhoI; and both PCR amplified ADH5 and linearized
pET28b were gel purified. Ligation was performed according to manufacturer’s protocol
and the ligated plasmid DNA was transformed directly into chemically competent DH5
E.coli. Colonies were screened using diagnostic restriction enzyme digest and later by
partial sequencing (Robart’s Research Institute, London Regional Genomics Center,
London, Ontario, Canada). The final recombinant GSNOR contains two 6X-histidine
tags, one at each terminus.
2.3.5 GSNOR expression and purification
pET28b_ADH5 was transformed into BL21(DE3) E.coli. This plasmid encodes full
length human GSNOR with terminal 6X-histidine tags to facilitate purification. A single
colony from the transformation plate was inoculated into 25 mL of 2X YT medium
containing 50 µg/mL kanamycin and the culture was grown overnight at 37°C with
shaking. This overnight starter culture was then used to inoculate 1L of 2X YT medium
containing 50 µg/mL kanamycin and the culture was again grown at 37°C until optical
density reached approximately 0.6. At this point, GSNOR expression was induced by the
addition of IPTG to a final concentration of 0.4 mM. The induced culture was grown for
an additional 24 hours at room temperature with shaking before cells were harvested by
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centrifugation (4000 g, 30 minutes, 4°C). Following centrifugation, the supernatant was
discarded and the bacterial cell pellet was resuspended in lysis buffer (50 mM Tris-HCl
pH 8, 150 mM NaCl, 15 mM imidazole, 1 mM DTT, 1 mM PMSF, 0.5% Triton X-100,
50 µg/mL DNase I and 100 µg/mL lysozyme). The crude lysate was incubated on ice for
30 minutes and further lysed by pulse sonication (20 seconds on, 20 seconds off, 30
cycles). Another round of centrifugation (11300 g, 30 minutes, 4°C) was performed to
clarify the lysate and the clarified supernatant was applied to nickel affinity column
(Sigma P6611) pre-equilibrated with lysis buffer. Affinity purification was performed
strictly following manufacturer’s protocol published by Sigma Aldrich with some
modifications in buffer composition. The wash buffer contains 50 mM Tris-HCl pH 8,
150 mM NaCl and 50 mM imidazole while the elution buffer contains 50 mM Tris-HCl
pH 8, 150 mM NaCl and 300 mM imidazole. Finally, the eluted protein was buffer
exchanged into storage solution (58 mM Na2HPO4, 17 mM NaH2PO4, 68 mM NaCl, 15%
glycerol) using Amicon centrifugal filter (Millipore UFC903008). When stored at -80°C,
purified GSNOR is stable and can retain its activity for at least 6 months.
2.3.6 GSNOR enzyme assay using GSNO as the substrate
NADH stock solution (20 mM) was prepared with MilliQ water. GSNO stock solutions
(10 mM and 1 mM) were prepared fresh daily using PBS. Total reaction volume was kept
at 500 µL using PBS as the reaction buffer. Each reaction contained 80 µM NADH and
indicated concentration of GSNO. Reaction was initiated by the addition of purified
GSNOR (1 µg) and the rate of NADH consumption was quantified by measuring the rate
of absorbance decrease at 340 nm. Each reaction was monitored for 120 seconds using
Agilent 8453 UV/Vis spectrophotometer at 25°C.
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2.3.7 GSNOR enzyme assay using OAbz-GSNO as the substrate
OAbz-GSNO concentration was determined by measuring its absorbance at 320 nm (ε ≈
2800 M-1 cm-1). Necessary dilutions were made using PBS. NADH stock solution (20
mM) was prepared using MilliQ water. Total reaction volume was kept at 500 µL using
PBS as the reaction buffer. Each reaction contained 80 µM NADH and indicated
concentration of OAbz-GSNO ranging from 0 to approximately 720 µM. Reaction was
initiated by the addition of purified GSNOR (1 µg) and initial reaction rates were
determined by monitoring fluorescence increase (excitation 312 nm; emission 415 nm)
for 2 minutes using Cary Eclipse fluorescence spectrophotometer.
2.3.8 GSNOR inhibition studies
Stock solutions (50 mM) of the GSNOR-specific inhibitors N6022 and C3 were prepared
using DMSO. Similar to the assay mentioned in Section 2.3.7, total reaction volume was
500 µL and each reaction contained 40 µM NADH, 1 µg GSNOR and various amounts of
inhibitor. The range of inhibitor concentration studied was 0 to 1000 nM for N6022 and 0
to 50 µM for C3. Reaction was initiated by adding 110 µM OAbz-GSNO and changes in
fluorescence were monitored for 2 minutes.
2.3.9 Isolation and culture of murine lung endothelial cells
C57BL/6 mice (4 – 6 weeks) were anesthetized by CO2 inhalation. After the animal’s
skin was cleaned with 70% ethanol, lung tissues were removed and placed in a 50 mL
conical tube containing DMEM and shipped to Cell Biologics (Chicago, Il) for isolation
of primary lung endothelial cells. Tissue slices were prepared, washed and suspended in
Hanks balanced saline solution (HBSS). After excess HBSS was removed, tissue slices
were minced and transferred to a sterile tube. Minced tissues were digested and the
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released cells were harvested by centrifugation. Cells collected were incubated with
primary antibody against platelet/endothelial cell adhesion molecule 1 (PECAM-1),
followed by the addition of magnetic beads pre-coated with secondary antibody. Finally,
cells released from the magnetic beads were washed and cultured on gelatin coated
culture dishes. These primary lung endothelial cells were characterized by their typical
cobblestone morphology, PECAM-1/CD31 and VE-cadherin expression as well as DilAc LDL uptake. Isolated endothelial cells were grown in complete mouse endothelial cell
medium (Cell Biologics) supplemented with attachment factor (Cell Biologics). Cells
between passage 3 and 7 were used for all subsequent studies.
2.3.10 Live cell imaging
Primary pulmonary endothelial cells from C57BL/6 mice were grown on glass coverslips,
washed 2 times with Dulbecco’s phosphate buffered saline (DPBS with Ca2+ and Mg2+)
and loaded with 1.85 mM OAbz-GSNO for 10 mins at 37°C in the cell culture incubator.
Unloaded cells were used as negative controls. For studies involving GSNOR inhibitors,
cells were first treated with either 25 µM C3 or 25 µM N6022 for 1 hour at 37°C and
then loaded with OAbz-GSNO. Their respective paired controls (+ inhibitor / - OAbzGSNO) were included for comparison. Following OAbz-GSNO loading, cells were
washed 4 times with DPBS before imaging. When cells were ready to be imaged, the
coverslip with cells was placed in a stainless steel chamber and mounted on Zeiss 780
confocal microscope stage. Cells were imaged in DPBS with 40X NA1.1 water objective.
During the course of imaging, cells were maintained at 37°C using stage temperature
control and under humidified gas flow. The compound OAbz-GSNO was excited using
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2p 740 nm at 3% and emission was collected from 411-482 nm range with 800v PMT at
5 second intervals over 5 minutes using Time Series.
2.4 Results and Discussion
2.4.1. OAbz-GSNO synthesis
OAbz-GSNO synthesis consists of two steps. In the first step, reduced glutathione is
reacted with acidified nitrite to form GSNO (Figure 2.4.1-1 A). This well-characterized
reaction is fast with high yields. Product can be precipitated using acetone and stored as
solid powder. When stored at -20°C, GSNO is stable for at least 6 month. In the second
step, OAbz-GSNO is formed by the nucleophilic attack of the α-amino group of
glutathione on the anhydride carbonyl of isatoic anhydride (Figure 2.4.1-1 B). The final
product OAbz-GSNO can either be lyophilized or stored directly as a solution in -80°C.
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Figure 2.4.1-1 OAbz-GSNO synthesis is a two-step process
(A) Synthesis of GSNO using GSH and acidified sodium nitrite. (B) GSNO reacts with
isatoic anhydride to produce OAbz-GSNO.
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2.4.2 NMR characterization
NMR spectra were used to confirm the success of OAbz-GSNO synthesis. By
comparison to the starting material GSNO, attachment of the O-aminobenzoyl group
resulted in significant chemical shift for the glutamate α proton (3.74 ppm to 4.22 ppm)
as well as the appearance of aromatic proton signals (Figures 2.4.2-1 and 2.4.2-2, Table
2.4.2). These observations are in agreement with predicted chemical shift changes, and
provide strong evidence for the successful synthesis of OAbz-GSNO.
In addition to OAbz-GSNO, NMR also identified a minor chemical species in
which the nitroso-group is absent (i.e. OAbz-GSH, peaks denoted by *). Formation of
OAbz-GSH is most likely due to small amounts of GSH present in the starting material
rather than NO loss post-synthesis as peaks corresponding to GSH were detected in the
starting material.
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Figure 2.4.2-1 1H NMR of GSNO
Lyophilized GSNO was dissolved in minimum volume D2O. Spectrum was collected on
a Bruker 500 MHz Avance III spectrometer using a BBFO probe.
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Figure 2.4.2-2 1H NMR of OAbz-GSNO
Lyophilized OAbz-GSNO was dissolved in minimum volume D2O. Spectrum was
collected on a Bruker 500 MHz Avance III spectrometer using a BBFO probe.
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Table 2.4.2 1H NMR chemical shifts of GSNO and OAbz-GSNO
2.04 (m, 2H, Glu Hβ)
2.33 (t, 2H, Glu Hγ)
GSNO

3.74 (t, 1H, Glu Hα)

(500 MHz, D2O, δ)

3.84 (s, 1H, Gly Hα)
3.87 (b, 1H, Cys Hβ)
4.00 (b, 1H, Cys Hβ)
4.54 (t, 1H, Cys Hα)
1.94 (m, 1H, Glu Hβ)
2.12 (m, 1H, Glu Hβ)
2.28 (t, 2H, Glu Hγ)

OAbz-GSNO

3.55 (s, 2H, Gly Hα)

(500 MHz, D2O, δ)

3.80 (b, 1H, Cys Hβ)
3.96 (b, 1H, Cys Hβ)
4.22 (q, 1H, Glu Hα)
4.52 (t, 1H, Cys Hα)
6.75-7.90 (aromatic H)

Abbreviations: δ, chemical shift in parts per million (ppm) downfield from the standard
Multiplicities: s, singlet; t, triplet; q, quartet; m, multiplet; b, broadened

45

2.4.3 Fluorescence properties of OAbz-GSNO
Based on previous studies with fluorescently tagged S-nitrosothiols [205-207], the –SNO
group can quench a fluorophore if two conditions are met:
1) The fluorophore excitation spectrum overlaps the –SNO absorbance spectrum.
2) The overall structure of the molecule permits the fluorophore and the –SNO moiety to
be in close physical proximity.
The fluorophore O-aminobenzoyl fulfills both conditions. First, the excitation spectrum
of O-aminobenzoyl exhibits λmax at around 312 nm. This overlaps the –SNO absorbance
spectrum with its λmax at around 335 nm. Second, since GSNO is a small molecule, its
physical structure allows O-aminobenzoyl and –SNO to come into close proximity,
resulting in fluorescence quenching. Chemical changes to the –SNO functionality, such
as loss of NO via denitrosation or reduction of –SNO to –SNHOH by GSNOR, would
lead to a loss in spectra overlap (Figure 2.4.3-1). This in turn results in enhanced
fluorescence that could be detected.
Consistent with this concept, OAbz-GSNO is only weakly fluorescent upon
synthesis. Denitrosation mediated by the addition of strong reducing agent DTT increases
OAbz-GSNO fluorescence by approximately 14 fold (Figures 2.4.3-2). This increase in
fluorescence is the direct consequence of NO loss, which removes the quenching effect.
In addition to OAbz-GSNO, Eosin-GSNO and dansyl-GSNO were also
synthesized and screened for their applicability. Both Eosin-GSNO and dansyl-GSNO
exhibit insufficient fluorescence quenching and are determined to be poor substrates for
GSNOR.
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Figure 2.4.3-1 Spectral difference between GSNO and NH2OH
GSNO exhibits maximum absorbance at 335 nm. This overlaps with the O-aminobenzoyl
excitation spectrum. Hydroxylamine (NH2OH), on the other hand, does not absorb in this
wavelength range.
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Figure 2.4.3-2 DTT mediated OAbz-GSNO denitrosation results in significant
fluorescence enhancement
(A) Addition of DTT to the final concentration of 10 mM increases OAbz-GSNO
fluorescence (excitation 312 nm, emission 415 nm) by approximately 14 fold. (B)
Fluorescence emission spectra of 75 µM OAbz-GSNO before (dash line) and after (solid
line) the addition of 10 mM DTT. Excitation wavelength is set to 312 nm.
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2.4.4 OAbz-GSNO is a fluorogenic substrate for GSNOR
To assess whether OAbz-GSNO works as a fluorogenic substrate for GSNOR in vitro,
full length human ADH5 (NCBI reference sequence NM_000671.3), which encodes
GSNOR, was cloned into an E. coli expression vector for recombinant protein
production. Cloning success was verified by diagnostic restriction digest and partial DNA
sequencing.
The recombinant GSNOR protein carries two poly-histidine tags, one at each
terminus, to facilitate Nickel affinity purification. Purified GSNOR exhibits monomeric
mass of approximately 40 kDa (Appendix C). Conventional NADH consumption assay
was used to determine whether the purified GSNOR is active in vitro. As shown in
Figure 2.4.4-1, in the absence of substrate, absorbance at 340 nm was relatively constant.
When substrate (50 µM GSNO) was included in the reaction mixture, GSNOR catalyzed
GSNO reduction led to a rapid decrease in absorbance as both GSNO and the cofactor
NADH were being consumed.
Next, a series of experiments were performed using OAbz-GSNO as the substrate.
Results show that GSNOR mediated reduction of OAbz-GSNO is capable of removing
the quenching effect and causes OAbz-GSNO fluorescence to increase in a time
dependent manner (Figure 2.4.4-2). Specifically, OAbz-GSNO is stable in the absence of
GSNOR for up to 45 minutes, as evidenced by no fluorescence increase. Upon the
addition of GSNOR, fluorescence begins to increase over time. After 45 minutes,
approximately 10 fold increase in fluorescence was observed. When compared to the
chemical reduction of OAbz-GSNO by DTT, the full 14 fold increase in fluorescence was
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not observed in this enzymatic reaction since not all of the OAbz-GSNO was converted
to product within 45 minutes.
The kinetic parameters of GSNOR using OAbz-GSNO as the substrate were also
assessed. Time dependent changes in fluorescence were monitored as a function of
OAbz-GSNO concentration in the presence of catalytic amounts of purified GSNOR. The
initial rates of fluorescence change per unit time were hyperbolic with an apparent Km of
320 µM (Figure 2.4.4-3). Vmax was estimated to be 19.1 fluorescent units per minute,
which equals approximately 1.65 nmol –SNO reduced per minute based on the
calibration curve (Figure 2.4.4-4). Both Km and Vmax were calculated using the Excel
analysis tool Solver. The observed Km value of 320 µM for OAbz-GSNO is much larger
than the previously reported Km value of 28 µM for GSNO [54, 111]. This is likely due to
the bulk of the O-aminobenzoyl group not being well accommodated by the GSNOR
active site.
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Figure 2.4.4-1 Purified recombinant GSNOR is active
Absorbance at 340 nm was monitored as a function of time. Each reaction contains 1 µg
GSNOR, 80 µM NADH, and GSNO at indicated concentrations. PBS was used as the
reaction buffer.
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Figure 2.4.4-2 GSNOR mediated reduction of OAbz-GSNO leads to increased
fluorescence
Comparison of OAbz-GSNO (10 µM) fluorescence emission spectra in the presence of
NADH (10 µM) without GSNOR at t= 0, 5 and 45 minutes; as well as in the presence of
GSNOR (6 µg) and NADH (10 µM) at t= 0, 5, 15, 30 and 45 minutes. PBS was used as
the reaction buffer. Excitation wavelength was set to 312 nm.
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Figure 2.4.4-3 Kinetic characterization of OAbz-GSNO
Initial rates of OAbz-GSNO fluorescence increase (excitation at 312 nm, emission at 415
nm) were determined as a function of OAbz-GSNO concentration in the presence of
GSNOR (1 µg) and NADH (80 µM). Error bars represent standard deviation (n=5).
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Figure 2.4.4-4 OAbz-GSNO calibration curve
Known amounts of OAbz-GSNO were fully reduced using DTT. Quantitative changes in
fluorescence (excitation at 312 nm, emission at 415 nm) were recorded. Error bars
represent standard deviation (n=5).
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2.4.5 In vitro GSNOR inhibition studies
To further confirm that the observed fluorescence increase was specifically due to
GSNOR mediated –SNO reduction, GSNOR inhibitors N6022 and C3 were used (Figure
2.4.5-1). Both inhibitors were able to prevent OAbz-GSNO fluorescence increase in
vitro. This demonstrates substrate fluorescence is responsive to GSNOR activity.
Based on this set of experiments, the IC50 of N6022 was estimated to be 21.1 nM
± 3.1 nM (Figure 2.4.5-2 A); while the estimated IC50 of C3 was 1.9 µM ± 0.2 µM
(Figure 2.4.5-2 B). The IC50 value obtained for C3 was very close to the previously
reported value of 1.1 µM [124]. On the other hand, the estimated IC50 of 21.1 nM for
N6022 was slightly larger than the reported value of 8 nM [126]. This lower affinity
observed for N6022 with OAbz-GSNO is likely related to the fact that N6022, as an
uncompetitive inhibitor, binds to the enzyme-substrate complex. The higher IC50
observed suggests that the bulkiness of the O-aminobenzoyl moiety might decrease
interactions between active site bound substrate and N6022. Conversely, noncompetitive
inhibitors (such as C3) bind to a site peripheral to the active site. In this case, the binding
of C3 was not affected, as evidenced by the close to reported IC50 obtained using OAbzGSNO as the substrate.
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Figure 2.4.5-1 Structures of GSNOR-specific inhibitors
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Figure 2.4.5-2 GSNOR-specific inhibitors N6022 and C3 inhibit GSNOR-mediated
OAbz-GSNO reduction in vitro
(A) Initial rates of OAbz-GSNO fluorescence change were monitored at 415 nm
(excitation at 312 nm). Each reaction contained 110 µM OAbz-GSNO, 1 µg GSNOR, 80
µM NADH and varying amounts of N6022. (B) Similarly, initial rates of OAbz-GSNO
fluorescence change were monitored at 415 nm with varying amounts of C3 included in
each reaction. Error bars represent standard deviation (n=3).
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2.4.6 OAbz-GSNO is cell permeable
Confocal microscopy was used to assess membrane permeability of OAbz-GSNO. GSNO
alone is largely hydrophilic and does not readily cross cell membranes. However, the
addition of aromatic groups to make charged hydrophilic compounds membrane
permeable is a well-established technique in pharmacology [208]. By exposing primary
endothelial cells to OAbz-GSNO and monitoring fluorescence at 410 nm, strong
fluorescence was observed in the perinuclear/Golgi region of these cells (Figure 2.4.6-1
B), clearly demonstrating that OAbz-GSNO is cell membrane permeable. Furthermore,
GSNOR is localized to the same subcellular region as visualized by immunofluorescence
(Figure 2.4.6-1 A). Since both enzyme and substrate are in the same subcellular
compartment, this will likely facilitate GSNOR mediated reduction of OAbz-GSNO.
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Figure 2.4.6-1 GSNOR and OAbz-GSNO exhibit similar subcellular localization
patterns in primary murine lung endothelial cells
(A) Primary mouse lung endothelial cells were grown on coverslips, fixed with 3.7%
formaldehyde and permeabilized with digitonin. GSNOR expression was visualized using
anti-GSNOR primary antibodies and Alexa Fluor 488 secondary antibodies. (B) Primary
mouse lung endothelial cells were grown on glass coverslips and loaded with 1.85 mM
OAbz-GSNO for 10 minutes at 37°C. Fluorescence from live cells was visualized using
Zeiss 780 confocal microscope. Imaging studies were performed by Dr. Lisa Palmer and
colleagues at the University of Virginia.
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2.4.7 Live-cell imaging studies
Similar to the in vitro experiments, live-cell imaging studies demonstrate that the
fluorescence of OAbz-GSNO loaded cells increases over time, indicating that the –SNO
functionality of OAbz-GSNO is being altered (Figure 2.4.7-1). To determine if the
observed fluorescence change is due to endogenous cellular GSNOR activity, cells were
treated with GSNOR-specific inhibitors (N6022 or C3) prior to OAbz-GSNO loading.
Upon GSNOR inhibition, the rate of fluorescence increase in OAbz-GSNO loaded cells
is reduced to levels comparable to no treatment control cells (Figure 2.4.7-1). This offers
strong evidence that the observed increase in live cell fluorescence is reporting on
endogenous GSNOR activity.
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Figure 2.4.7-1 N6022 and C3 inhibit GSNOR-mediated fluorescence increase in cells
loaded with OAbz-GSNO
(A) Average perinuclear fluorescence (PF), in all cells in the field of view, was obtained
from time-image stack, digitized with ImageJ and the Time Series Analyzer V3 plugin.
Blue circles – cells were loaded with 1.85 mM OAbz-GSNO; red circles – cells were
first treated with 25 µM N6022 for 1 hour, and then loaded with OAbz-GSNO; purple
circles – cells were first treated with 25 µM C3 for 1 hour, and then loaded with OAbzGSNO; green circles – no treatment control cells. (B) Images collected from stack at t=0
and t=150 second (t=120 second for C3) with PF values indicated. Imaging studies were
performed by Dr. Lisa Palmer and colleagues at the University of Virginia.
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2.5 Conclusion
In this chapter, we report the synthesis and characterization of OAbz-GSNO as a
fluorogenic substrate for the enzyme GSNOR (Figure 2.5). The fluorescence of OAbzGSNO can be turned on by either chemical or enzyme-mediated reduction of its –SNO
moiety in vitro. Furthermore, this substrate can be taken up by primary cells in culture
and accumulates in the same subcellular compartment as GSNOR. Results from live-cell
imaging studies demonstrate endogenous GSNOR activity results in detectable increases
in OAbz-GSNO fluorescence; and this increase in fluorescence is abolished by GSNOR
inhibitor treatment. To the best of our knowledge, OAbz-GSNO is the first compound
which is capable of reporting on endogenous GSNOR activity in live cells.
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Figure 2.5 OAbz-GSNO is a fluorogenic substrate for GSNOR
OAbz-GSNO experiences fluorescence quenching and exhibits minimal fluorescence.
Chemical or enzymatic reduction of its –SNO functional group leads to significant
fluorescence increase. OAbz-GSNO is membrane permeable and can be used to assess
endogenous GSNOR activity in live cells.
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CHAPTER 3
Investigations into the Regulation of S-nitrosoglutathione Reductase Activity at the
Post-Translational Level
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3.1 Introduction
S-nitrosoglutathione reductase (GSNOR) is an evolutionarily conserved, multi-functional
enzyme. It can effectively catalyze both the oxidation of hydroxymethylglutathione
(HMGSH) [65], and the reduction of S-nitrosoglutathione (GSNO) [54, 107]. As a result
of these enzymatic activities, functional studies of GSNOR have largely focused on its
involvement in cellular formaldehyde detoxification; as well as S-nitrosothiol (SNO)
homeostasis and nitric oxide (NO) signaling. Despite its universal pattern of expression
[85] and demonstrated involvement in human physiology, not much is known regarding
the regulation of its activity, especially at the post-translational level.
Structurally, GSNOR is a metalloenzyme with two coordinated zinc ions (Zn2+)
per subunit. Primary amino acid sequence analysis reveals a CxxC zinc finger motif as a
part of the structural zinc binding site. In addition to metal binding, the CxxC motif, in
which two cysteine residues are separated by two other residues, is a well characterized
redox motif [209]. Proteins such as thioredoxins and protein disulfide isomerase (PDI)
use this motif for the formation, reduction and isomerization of protein disulfide bonds
[210-212]. It is widely accepted that the two residues in between the cysteines exert
substantial influences on the redox potential of this motif. More recently, Kimura et al.
studied the conserved lysine residue immediately following the CxxC motif in PDI and
demonstrated that this lysine residue (CxxCK) significantly increases PDI isomerase
activity [213]. Acetylation of this lysine was subsequently suggested as a possible posttranslational modification involved in the regulation of PDI activity [214]. Interestingly,
the zinc binding CxxC motif within GSNOR is also flanked by a highly conserved lysine
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residue (CxxCK101). Whether K101 contributes to the regulation of GSNOR activity is
currently unknown.
This chapter focuses on in vitro kinetic evaluation of wild-type and mutant
GSNOR to assess the role of K101 and to investigate potential post-translational
regulations of GSNOR activity.
3.2 Materials
Acetic anhydride (320102), DNase I (DN25), glutathione, reduced (G4251), imidazole
(I0125), isopropyl

β-D-1-thiogalactopyranoside (I6758), lysozyme (L7651), β-

nicotinamide adenine dinucleotide, reduced (N8129), phenylmethylsulfonyl fluoride
(7626), sodium nitrite (S2252), sodium phosphate dibasic (S7907), sodium phosphate
monobasic (S8282) and Triton X-100 (T9284) were purchased from Sigma-Aldrich.
Glycerol (G3700) and sodium chloride (S2830) were purchased from ACP Chemicals.
Kanamycin (BP906) and Tris-HCl (BP153) were purchased from Fisher Scientific.
Dithiothreitol (100597) was purchased from MP Biomedicals.
3.3 Methods
3.3.1 Computational modeling and simulations
The Molecular Operating Environment (MOE, 2013.08; Chemical Computing Group Inc.
Montréal, QC, Canada) software package was used to perform all docking and molecular
dynamics (MD) simulations.
GSNOR crystal structure (PDB ID: 3QJ5) was used as the template for the
investigation. Initial crystallographic data was prepared using MOE software by
removing the waters and resolving the system up to 6 Å away from any residue. The
structure was then allowed to relax using the AMBER12: EHT force field to remove any
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strain from the preparation of the protein structure. Finally, in order to allow for thermal
relaxation and multiple conformers generation, the minimized structure was used as
starting point for a 3 ns MD simulation. An estimated average structure found in the
production run was selected for additional analysis.
For docking experiments, the substrate GSNO was docked into its known active
site using the induced fit formulism. Virtual screening was then employed to identify
other potential GSNO binding sites. To evaluate the top poses, London dG scoring
function was used with the AMBER12: EHT force field refinement keeping the top 10
scores.
3.3.2 GSNO synthesis
Reduced glutathione (5 mmol) was dissolved in 8 mL of cold water and 2.5 mL of 2 M
HCl. To this solution, 5 mmol of sodium nitrite was added and the reaction was stirred at
4°C in the dark for 40 minutes. After 40 minutes, GSNO was precipitated using 10 mL of
cold acetone. The precipitate was collected via filtration, washed with cold water (5 X 1
mL), cold acetone (3 X 10 mL), and lyophilized for storage at -20°C.
3.3.3 Site-directed mutagenesis
The residue Lys101 of human GSNOR was mutated to either alanine (K101A) or
glutamine (K101Q) using Q5 Site-Directed Mutagenesis Kit (New England BioLabs
E0554). PCR primers were designed to be end-to-end with the forward primer carrying
the mutagenic sequence resulting in single amino acid substitution. The following
primers were used:
K101A Forward

5’ – TGG AGA ATG CGC ATT TTG TCT AAA TCC – 3’
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K101A Reverse

5’ – CAC TGT GGG ATG TAA AGT G – 3’

K101Q Forward

5’ – GGA GAA TGC CAA TTT TGT CTA AAT CCT – 3’

K101Q Reverse

5’ – ACA CTG TGG GAT GTA AAG TG – 3’

PCR reaction was set up according to manufacturer’s recommendations and thermal
cycling conditions were optimized for each primer set. The resultant PCR product was
treated with Kinase, Ligase, Dpn1 enzyme mix according to manufacturer’s protocol and
used to transform chemically competent DH5 E.coli (New England BioLabs C2987).
Individual colonies from the transformation plates were selected and each colony was
inoculated into 3 mL of LB medium (with 50 µg/mL kanamycin) for overnight growth at
37°C. Plasmid DNA was then isolated from these cultures using a standard bacterial
miniprep procedure (Qiagen). Isolated plasmid DNA was resuspended in TE buffer and
sequenced at Robart’s Research Institute (London Regional Genomics Center, London,
Ontario, Canada) using T7 sequencing primer. Successful mutants were selected for
subsequent transformation and protein expression.
3.3.4 Protein expression and purification
Expression

plasmids

pET28b_GSNOR,

pET28b_GSNOR_K101A

and

pET28b_GSNOR_K101Q were individually transformed into chemically competent
BL21(DE3) E.coli (New England BioLabs C2527). Recombinant proteins contain
terminal 6X-histidine tags to facilitate purification. A single colony from the
transformation plate was inoculated into 25 mL of 2X YT medium containing 50 µg/mL
kanamycin and the culture was grown overnight at 37°C. This overnight starter culture
was then used to inoculate 500 mL of 2X YT medium containing 50 µg/mL kanamycin
and the culture was grown at 37°C until optical density reached approximately 0.6. At
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this point, protein expression was induced by the addition of IPTG to a final
concentration of 0.4 mM. The induced culture was grown for an additional 24 hours at
room temperature before cells were harvested by centrifugation (4000 g, 30 minutes,
4°C). Following centrifugation, supernatant was discarded and the bacterial cell pellet
was resuspended in 15 mL of lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 15 mM
imidazole, 1 mM DTT, 1 mM PMSF, 0.5% Triton X-100, 50 µg/mL DNase I and 100
µg/mL lysozyme). The crude lysate was incubated on ice for 30 minutes and further lysed
by pulse sonication (20 seconds on, 20 seconds off, 30 cycles). Another round of
centrifugation (11300 g, 30 minutes, 4°C) was performed and the clarified supernatant
was applied to nickel affinity column (Sigma P6611) pre-equilibrated with lysis buffer.
Affinity purification was performed strictly following manufacturer’s protocol published
by Sigma Aldrich with some modifications in buffer composition. The wash buffer
contained 50 mM Tris-HCl pH 8, 150 mM NaCl and 50 mM imidazole while the elution
buffer contained 50 mM Tris-HCl pH 8, 150 mM NaCl and 300 mM imidazole. Finally,
eluted protein was buffer exchanged into storage solution (58 mM Na2HPO4, 17 mM
NaH2PO4, 68 mM NaCl, 15% glycerol) using Amicon centrifugal filter (Millipore
UFC903008). When stored at -80°C, purified proteins are stable and can retain their
activity for at least 6 months in the absence of repeated freeze-thaw cycles.
3.3.5 Kinetic assays
NADH stock solution (20 mM) was prepared with MilliQ water. GSNO stock solutions
(10 mM and 1 mM) were prepared fresh daily using PBS. Total reaction volume was kept
at 500 µL using PBS as the reaction buffer. The various GSNO and NADH
concentrations used in the assays are noted in the Figure legends.
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For the set of GSNO pre-treatment experiments, wild-type and mutant GSNOR
were incubated with 0.5 mM GSNO in the dark for 30 minutes at room temperature.
Following incubation, unreacted GSNO was removed using Zeba desalting columns
(Fisher Scientific 89882). For chemical acetylation experiments, acetic anhydride (1 M)
stock solution was prepared using methanol due to its reactivity. Wild-type and mutant
GSNOR were then treated with 20 mM acetic anhydride for 1 hour at room temperature
before enzyme activities were assayed. Each individual reaction was initiated by the
addition of enzyme (2 µg) and decreases in absorbance at 340 nm were monitored for 90
seconds using Agilent 8453 UV/Vis spectrophotometer.
3.3.6 Immunoblotting
Wild-type and mutant GSNOR were treated with 20 mM acetic anhydride for 1 hour at
room temperature. Enzymes mock-treated with equal volume of methanol or GSNOR
storage buffer were used as controls. Following treatment, samples were resolved using
10% SDS-PAGE gels and transferred onto polyvinylidene difluoride (PVDF)
membranes. Blocking was carried out for 1 hour at room temperature using 5% skim
milk. Membranes were then incubated with primary antibodies against acetyl-lysine
(1:1000; Abcam ab61384) or 6X histidine (1:1000; Signal Chem H99-61M) overnight at
4°C, washed 3 times with TBST, and incubated with HRP-conjugated secondary
antibody (1:5000; Abcam ab97023) for 1 hour. Finally, the membranes were washed 3
times again and visualized using enhanced chemiluminescence reagents (Thermo
Scientific 34095).
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3.4 Results and Discussion
3.4.1 Computational modeling and simulations
GSNOR is a dimeric protein. Each subunit contains a CGEC motif (Figure 3.4.1-1 A).
This motif participates in the coordination of GSNOR structural zinc. We are interested
in the highly conserved lysine residue adjacent to the CGEC motif (CGECK101) and
whether acetylation of K101 affects GSNOR function.
Computational modeling and molecular dynamic simulations were performed to
predict changes due to K101 acetylation. Results show modification of K101 leads to
significant alterations in protein structure within the structural zinc binding site (Figure
3.4.4-1 B). This is associated with changes in the distance between GSNOR structural
zinc and each of the four Cys residues (C97, C100, C103 and C111) involved in its
coordination (Table 3.4.1-1). Cysteine thiol pKa values were also predicted based on
average protein structures. Interestingly, the predicted thiol pKa for C97 increases from
6.33 to 12.21 following K101 acetylation; while the pKa for C111 increases from 6.26 to
8.23 (Table 3.4.1-2). Higher pKa values do not favour thiolate (-S-) formation, which
could negatively affect cysteine’s ability to coordinate zinc. The predicted increase in
thiol pKa for C97 and C111 is also correlated with increased distance to the zinc they
coordinate. This could be due to weakened interaction between the two.
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A

B

Figure 3.4.1-1 Acetylation of Lys101 effects GSNOR protein structure around the
structural zinc binding site
(A) GSNOR is a dimeric protein. Each subunit contains a CxxC motif as part of the
structural zinc binding site (shown in orange). (B) Average protein structures of
unmodified wild-type GSNOR (magenta) and K101_acetylated wild-type GSNOR (blue)
from MD simulations were overlaid for comparison.
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Table 3.4.1-1 Distance (Å) between GSNOR structural Zn and Cys(S)
Residue

GSNOR WT

GSNOR K101A

GSNOR K101Q

GSNOR
K101Acetylated

C97

6.41

4.87

6.75

9.20

C100

10.21

7.35

5.82

5.84

C103

6.06

12.53

8.39

8.59

C111

5.44

8.13

10.60

9.81

GSNOR K101Q

GSNOR

Table 3.4.1-2 Predicted cysteine thiol pKa
Residue

GSNOR WT

GSNOR K101A

K101Acetylated
C97

6.33

12.78

8.48

12.21

C100

8.80

6.60

4.96

8.62

C103

6.43

8.02

7.93

6.42

C111

6.26

4.00

9.58

8.23
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3.4.2 Kinetic parameters of wild-type and mutant GSNOR
To assess the role of the conserved lysine residue at position 101, site directed
mutagenesis was performed using human GSNOR (NM_000671.3) as the template.
Successful mutation from lysine (K) to either alanine (A) or glutamine (Q) was
confirmed by sequencing. Lysine to alanine substitution removes a positively charged
side chain, which could affect the protein microenvironment for the cluster of cysteine
residues (C97, C100, C103 and C111) involved in structural zinc binding. Out of the
naturally occurring amino acids, the structure of glutamine best resembles that of
acetylated lysine. Therefore, lysine to glutamine substitution will offer some insight
regarding the effect of K101 acetylation.
When kinetic parameters of wild-type and mutant GSNOR were assessed, it was
determined that wild-type GSNOR exhibits an apparent Km of 30.2 ± 0.89 µM towards
GSNO and a kcat of 2467 ± 57.9 min-1 (Figure 3.4.2-1). Both of these values are
comparable to previously reported Km of 28 µM and kcat of 2640 min-1 [54]. Catalytic
efficiency of GSNOR was calculated as kcat / Km. For the wild-type enzyme, catalytic
efficiency was determined to be 1360000 ± 9900 s-1M-1 (Table 3.4.2).
GSNOR K101A exhibits an apparent Km of 27.6 ± 1.65 µM towards GSNO and a
kcat / Km of 1330000 ± 69400 s-1M-1 (Figure 3.4.2-1, Table 3.4.2). Both of these
parameters are not significantly different from the wild-type enzyme, indicating that
K101 is not involved in substrate binding and does not directly participate in catalysis.
On the other hand, K101Q mutant shows an apparent Km of 29.2 ± 3.18 µM towards
GSNO and a kcat / Km of 1090000 ± 81600 s-1M-1 (Figure 3.4.2-1, Table 3.4.2). The
experimental Km for K101Q is also comparable to wild-type, but catalytic efficiency of
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this mutant decreased by approximately 20%. Since glutamine was chosen to mimic the
structure of acetylated lysine, the observed decrease in catalytic efficiency suggests
acetylation could be involved in the post-translational regulation of GSNOR activity.
Enzyme activity as a function of cofactor (NADH) concentration was evaluated
for wild-type and mutant GSNOR (Figure 3.4.2-2). Apparent Km towards NADH was
determined to be 34.2 ± 2.72 µM for wild-type GSNOR, 41.3 ± 1.31 µM for K101A, and
35.2 ± 0.81 µM for K101Q. Based on these Km values, it appears the K101A mutant
displays slightly reduced affinity for NADH. This could be due to some alterations in
protein structure as a result of the mutation.
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Figure 3.4.2-1 Michaelis-Menten kinetics of wild-type and mutant GSNOR
Initial reaction rates of wild-type GSNOR (WT), GSNOR K101A (K101A) and GSNOR
K101Q (K101Q) were determined by monitoring absorbance decrease at 340 nm.
Various GSNO concentrations (ranging from 0 µM to approximately 400 µM) were used.
Each reaction contains 80 µM NADH and is initiated by the addition of 2 µg of enzyme.
PBS (pH 7.4) was used as the reaction buffer. Error bars represent standard deviation
(n=3).
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Figure 3.4.2-2 GSNOR activity as a function of cofactor concentration
Initial reaction rates of wild-type GSNOR (WT), GSNOR K101A (K101A) and GSNOR
K101Q (K101Q) were determined by monitoring absorbance decrease at 340 nm. Each
reaction contains 200 µM GSNO and various concentrations of NADH (ranging from 0
to 200 µM). Reaction is initiated by the addition of 2 µg of enzyme. Error bars represent
standard deviation (n=3).
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Table 3.4.2 Kinetic parameters of wild-type and mutant GSNOR
Wild-type GSNOR
% of WT
Km

GSNO

(µM)

30.2 ± 0.89

100 ± 3.0

KmNADH (µM)

34.2 ± 2.72

100 ± 7.9

kcat (min-1)

2468 ± 57.9

100 ± 2.3

kcat / Km (x 103 s-1 M-1)

1360 ± 9.9

100 ± 0.7

GSNOR K101A
% of WT
KmGSNO (µM)

27.6 ± 1.65

92 ± 5.5

KmNADH (µM)

41.3 ± 1.3

121 ± 3.8*

kcat (min-1)

2205 ± 18.2

89 ± 0.7*

kcat / Km (x 103 s-1 M-1)

1330 ± 69.4

98 ± 5.1

GSNOR K101Q
% of WT
Km

GSNO

(µM)

29.2 ± 3.18

97 ± 10.5

KmNADH (µM)

35.2 ± 0.81

103 ± 2.4

kcat (min-1)

1893 ± 62.1

77 ± 2.5*

kcat / Km (x 103 s-1 M-1)

1090 ± 81.6

80 ± 6.0*

Values given as mean ± SD
*statistically significant (p < 0.05)
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3.4.3 Chemical acetylation of GSNOR
Lysine acetylation was discovered more than 50 years ago on N-terminal tails of nuclear
histone proteins [215, 216]. Since then, a large number of non-histone proteins have been
shown to be regulated by transient Nε-acetylation on select lysine residues [214, 217].
Previous findings in our lab suggest acetylation of the CxxC motif flanking lysine in PDI
affects its enzyme activity. From the previous section, we observed a decrease in GSNOR
catalytic efficiency when its CxxC flanking lysine was mutated to glutamine, suggesting
lysine modification may be involved in the regulation of GSNOR activity. In this section,
in vitro acetylation was performed on wild-type GSNOR and GSNOR K101A using
acetic anhydride. It is important to point out that this chemical acetylation method is not
specific as acetic anhydride could also modify amino acid residues other than lysine, such
as serine and threonine. As a result, caution must be exercised when interpreting
experimental findings. The rationale behind this set of experiment is if acetylation of
K101 affects GSNOR activity, then this effect should not be observed in the K101A
mutant.
First, immunoblots were produced to verify lysine residues were acetylated. For
both wild-type GSNOR and K101A, treatment with 20 mM acetic anhydride results in
strong signals when probed with anti-acetyl-lysine antibody (Figure 3.4.3-1 A).
Chemical acetylation appears to be correlated with decreases in enzyme activity for both
wild-type (~50% reduction) and alanine mutant (~45% reduction). Due to its reactivity,
using acetic anhydride to study lysine acetylation has some limitations. For example,
residues other than lysine may also become modified; and we cannot control which lysine
residue gets acetylated. Despite these drawbacks, the observed reduction in GSNOR
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activity following acetic anhydride treatment provides promising preliminary data for
acetylation mediated down regulation of GSNOR activity. Methanol control (GSNOR
treated with 2% methanol, without acetic anhydride) is included for comparison since
acetic anhydride stock solution is prepared using methanol. Surprisingly, K101A exhibits
~25% reduction in activity when treated with methanol while wild-type GSNOR is
unaffected (Figure 3.4.3-1 B). The underlying cause for this differential response is
currently unknown. From computational predictions, we know that K101 mutation is
associated with alterations in cysteine thiol pKa and protein structure in the vicinity of the
structural zinc binding site. However, causal relationship between these predicted
changes and enzyme’s susceptibility towards methanol-induced effects has yet to be
established. As a solvent, methanol does not have the same hydrogen bonding capacity as
water. This may perturb protein-solvent hydrogen bond network, thus affecting dynamic
properties of GSNOR. Differential response to methanol suggests even though kinetic
parameters were not dramatically different between wild-type GSNOR and K101A, some
other property of the enzyme must have been altered in the K to A mutant in order to
elicit this response.
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Figure 3.4.3-1 Effect of chemical acetylation on GSNOR activity
Chemical acetylation of wild-type GSNOR and GSNOR K101A was performed using
acetic anhydride. (A) Samples were run on SDS-PAGE gels and transferred to PVDF.
Membranes were probed with anti-acetyl-lysine and anti-His antibodies. (B) Enzyme
activity was measured as rate of absorbance decrease at 340 nm. Each reaction contains
80 µM NADH and 200 µM GSNO. Initial reaction rates are graphed as percentage of the
no treatment control group. Error bars represent standard deviation (n=4). *statistically
different from no treatment control. **statistically different from no treatment control and
methanol control.
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3.4.4 In vitro S-nitrosation studies
Earlier this year, Guerra et al. predicted potential S-nitrosation sites within GSNOR using
the software GPS-SNO and demonstrated S-nitrosation decreases enzyme activity in vitro
[218]. The group further suggested GSNOR can be S-nitrosated by its own substrate
GSNO and the transient down-regulation of activity permits robust nitric oxide signaling
[218]. Inhibition of enzyme activity by its own substrate seems paradoxical. This
signaling model proposed by Guerra et al., coupled with computationally predicted
cysteine thiol pKa changes following K101 mutation/modification, prompted us to
investigate whether GSNOR activity can be regulated by S-nitrosation; and whether
K101 mutation renders any of the zinc-coordinating cysteines more susceptible to
oxidation.
For this purpose, both wild-type GSNOR and K101A mutant were treated with
0.5 mM GSNO for 30 minutes before activities were assayed. Contrary to results
published by Guerra and colleagues, GSNO pre-treatment did not have any observable
effect on enzyme activity (Figure 3.4.4-1); suggesting either GSNOR is not modified by
its substrate GSNO, or modification has no effect on enzyme activity. To complement
this finding, biotin-switch or mass spectrometry should be performed to assess the Snitrosation status of GSNOR following treatment. Different S-nitrosating agents can also
be explored since protein S-nitrosation occurs via multiple mechanisms.
Similarly, treating GSNOR K101A with 0.5 mM GSNO did not effect enzyme
activity; demonstrating mutation of K101 did not make C97, C100, C103 or C111 more
susceptible to S-nitrosation despite predicted changes in pKa values. In this case, it is
highly likely that these 4 cysteine residues are not modified since modification would
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affect their ability to coordinate zinc, which would translate into significant attenuation of
enzyme activity. This finding is not unexpected as structural cysteine-zinc complexes are
usually chemically inert [219, 220].
GSNOR is a cysteine-rich protein. Human GSNOR contains a total of 15 cysteine
residues, 6 of which are involved in zinc binding. At the moment, not much is known
regarding the chemical reactivity of these residues and whether reversible S-nitrosation is
one of the mechanisms regulating GSNOR activity. Contrary to recently published
findings, our results show GSNO pre-treatment does not have any effect on GSNOR
activity. Additional research in this area is needed to address this discrepancy.
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Figure 3.4.4-1 GSNO pre-treatment does not affect GSNOR activity
(A) Wild-type GSNOR and (B) GSNOR K101A are treated with 0.5 mM GSNO for 30
minutes. Unreacted GSNO is removed using Zeba desalting columns. Enzyme activities
at various GSNO concentrations are assayed by monitoring the decrease in absorbance at
340 nm. Each reaction contains 200 µM NADH and is initiated by the addition of 2 µg of
either wild-type or mutant GSNOR. Error bars represent standard deviation (n=3).
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3.4.5 Potential allosteric GSNO binding site and implications for the regulation
of GSNOR activity
When looking at GSNOR activity as a function of GSNO concentration, the shape of the
Michaelis-Menten curve caught our attention. It appears to deviate from the classical
hyperbola and exhibits increased response to substrate at low concentrations. This let us
to speculate perhaps GSNOR could be rapidly activated by some factor. In addition,
semi-logarithmic transformation produced an asymmetrical S-curve (Figure 3.4.5-1 A),
which is characteristic of enzymes that do not conform to simple kinetics [221]. Hill plot
was also constructed to determine cooperativity (Figure 3.4.5-1 B). The Hill coefficient
of GSNOR (calculated as slope of the best fit line) was greater than 1, which indicates the
existence of some form of positive cooperation. Upon further investigation,
computational docking results suggest GSNOR may have an allosteric binding site for
GSNO near the structural zinc domain (Figure 3.4.5-3 A). MD simulations show
consistent interaction between GSNO and this putative allosteric region, which brings
forth the possibility that GSNO binding to this site could affect the activity of GSNOR.
Based on this model, Asn184 and Gly320 appear to interact with GSNO directly; while
Lys187 and Lys322 interacts indirectly through the solvent network of hydrogen bonds
(Figure 3.4.5-3 B). Docking scores, which is used to predict binding affinity, also
support the existence of an allosteric binding site for GSNO. Specifically, GSNO binding
to the known active site exhibits a score of -8.60; while GSNO binding to the putative
allosteric site has a score of -10.4 (low scores indicate stable systems and are associated
with favorable interactions.)
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Our hypothesis of allosteric regulation was tested using the fluorogenic substrate
OAbz-GSNO. GSNOR-mediated reduction of OAbz-GSNO was examined in the
absence, as well as in the presence, of GSNO. Results indicate including GSNO in the
reaction leads to enhanced OAbz-GSNO reduction, as evidenced by higher rates of
fluorescence increase (Figure 3.4.5-2). On the other hand, OAbz-GSNO fluorescence is
not affected by GSNO alone. Based on these observations, we propose GSNO binding to
the allosteric site enhances GSNOR activity.
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Figure 3.4.5-1 Logarithmic plots of GSNOR kinetics
Initial reaction rates of wild-type GSNOR are determined by monitoring absorbance
decrease at 340 nm. Each reaction contains 80 µM NADH and is initiated by the addition
of 2 µg enzyme. (A) Semi-logarithmic plot. (B) Hill plot.
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Figure 3.4.5-2 GSNO enhances GSNOR-mediated reduction of OAbz-GSNO
GSNOR activity is measured by monitoring fluorescence increase (excitation at 312 nm,
emission at 415 nm) due to OAbz-GSNO reduction in the absence of GSNO (circles) and
in the presence of 40 µM GSNO (diamonds). Each reaction contains 120 µM NADH and
various concentrations of OAb-GSNO. PBS is used as the reaction buffer. Reaction is
initiated by the addition of 2 µg of wild-type GSNOR. Error bars represent standard
deviation (n=3).
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Figure 3.4.5-3 Putative allosteric GSNO binding site
High resolution (1.9 Å) X-ray crystal structure of GSNOR from Homo sapiens (PDB ID:
3QJ5) was used as the base structure for GSNO docking. (A) Putative allosteric GSNO
binding site is near the structural zinc domain. (B) Predicted interactions between GSNO
and GSNOR based on the average structure from MD simulations.
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3.5 Conclusion
This chapter focuses on kinetic evaluation of GSNOR activity to identify potential
mechanisms of regulation. First, the role of CxxC flanking K101 was assessed by sitedirected mutagenesis. Results show mutation of K101 to glutamine leads to
approximately 20% reduction in catalytic efficiency. Since the structure of glutamine is
similar to the structure of acetylated lysine, K101 acetylation may represent a posttranslational modification involved in the down-regulation of GSNOR activity. Chemical
acetylation using acetic anhydride also results in decreased enzyme activity. This project
will be carried forward. In vitro acetylation using recombinant acetyltransferase and mass
spectrometry will be performed to provide unambiguous evidence regarding the site of
lysine acetylation and its effect on GSNOR activity.
Contrary to previously proposed model that S-nitrosation mediated by GSNO
attenuates GSNOR activity, treatment with 0.5 mM GSNO did not have any effect on
enzyme activity for both the wild-type and K101A mutant. Instead, our findings suggest a
different mode of regulation, in which GSNOR activity is enhanced when GSNO binds to
an allosteric site. This proposed mechanism would allow GSNOR to exhibit greater
activity when substrate is abundant, effectively restoring cellular homeostasis.
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CHAPTER 4
Functional Aspects of Neutral Sphingomyelinase II
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4.1 Introduction
Sphingolipids are major constituents of the plasma membrane in eukaryotic cells. This
class of lipids typically consists of a sphingosine backbone, a long chain fatty acid, and a
variable polar head group. Originally considered to serve only structural roles, these
lipids are now recognized as important participants in a wide range of signal transduction
pathways [222, 223]. In particular, sphingomyelin-based pathways have received
considerable attention in recent years. Structurally, sphingomyelin (SM) has a polar
phosphorylcholine head group and the composition of the long chain fatty acid varies
from tissue to tissue and can be either saturated or mono-unsaturated with 14 to 24
carbons [224, 225]. Results based on cell fractionation studies and degradation
experiments suggest that more than half of the cellular SM mass is confined to the plasma
membrane [226]. The exact percentage may vary from one cell type to another, though it
has been reported that cells with extensive plasma membrane recycling have a larger
fraction of SM in intracellular compartments [227].
SM’s role in signaling is multifaceted. Its hydrolysis generates bioactive
ceramide, a lipid second messenger molecule capable of modulating cellular events such
as cell cycle arrest, differentiation, inflammation and apoptosis [132-134]. SM hydrolysis
is specifically catalyzed by the family of enzymes known as sphingomyelinase (EC
3.1.4.12). This enzyme family is further divided into three groups (acid, neutral and
alkaline) based on their distinct catalytic pH optimum. Of the different forms of
sphingomyelinases identified and studied to date, the magnesium-dependent neutral
sphingomyelinase II (NSMase II) has emerged as the predominant sphingomyelinase
implicated in a diverse set of cellular functions and disease pathologies [180, 228].
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During recent years, a large number of studies have identified NSMase II as a mediator of
cellular stress response, mainly through the production of ceramide. Exposures to
oxidative stress [160, 163], pro-inflammatory cytokines [169], and anti-cancer
compounds [187, 229] can up-regulate NSMase II expression and activity, which
increases cellular ceramide levels to signal apoptosis or senescence.
In addition to ceramide generation, NSMase II catalyzed SM degradation may
also affect the formation of lipid rafts within the plasma membrane. Lipid rafts are
ordered microdomains enriched in SM and cholesterol. These microdomains are
detergent resistant and have been proposed to serve as platforms for the attachment of
different proteins involved in signaling [230]. Specific proteins can be selectively
included or excluded from these laterally organized microdomains, thus facilitating
various signaling events [231, 232]. A consistent ratio between SM and cholesterol needs
to be maintained in the plasma membrane to support lipid raft formation, and there is
evidence indicating plasma membrane SM and cholesterol levels are coordinately
regulated [233]. For example, reduction of SM level by the addition of purified bacterial
sphingomyelinase to cultured cells decreases membrane’s ability to solubilize cholesterol,
which leads to increased cholesterol esterification and transport to intracellular sites, as
well as down-regulation of cholesterol de novo synthesis [234-236]. Although NSMase II
was not directly implicated in these studies, it is reasonable to hypothesize that stress
induced NSMase II activation could also affect plasma membrane cholesterol content and
lipid raft formation.
Cortisol is the principle glucocorticoid hormone in humans. It is produced by the
adrenal cortex and released into circulation according to a distinct circadian pattern [237].
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Disruptions to this daily rhythm have been observed in patients with breast and ovarian
cancer [238]. In this chapter, cortisol exposure was used as a stressor and its effect on
NSMase II expression and activity were assessed. The ability of NSMase II to modulate
plasma membrane cholesterol content was also explored.
The regulation of NSMase II activity is not well understood and contradictory
findings have been reported. For instance, while Liu and Hannun observed physiological
concentrations of GSH can effectively inhibit NSMase II activity [188]; Dotson et al.
reported increases in activity in response to reducing agents, such as GSH and 2mercaptoethanol [239]. Despite these seemingly contradictory findings, cellular redox
environment clearly has an effect on NSMase II activity. In addition, human NSMase II
contains a total of 23 cysteine residues, for which the redox sensitivity has not been fully
assessed. Since our lab is interested in the post-translational modification S-nitrosation,
the last part of this project will focus on in vitro NSMase II activity in response to GSNO
treatment.
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4.2 Material
Ampicillin (A0166), cortisol (H0888), DNase I (DN25), imidazole (I0125), isopropyl βD-1-thiogalactopyranoside (I6758), lysozyme (L7651), magnesium chloride (M2570),
phenylmethylsulfonyl fluoride (7626), and Triton X-100 (T9284) were purchased from
Sigma-Aldrich. Sodium chloride (S2830) was purchased from ACP Chemicals.
Kanamycin (BP906) and Tris-HCl (BP153) were purchased from Fisher Scientific.
Dithiothreitol (100597) was purchased from MP Biomedicals. Fluoromount G (0100-01)
was purchased from Southern Biotech.
4.3 Methods
4.3.1 Cell culture
Triple negative breast cancer cells (HTB 126) were purchased from ATCC and
maintained in DMEM high-glucose medium (HyClone SH30022.01) supplemented with
10% fetal bovine serum (GIBCO 12483), 100 μg/mL streptomycin and 100 U/mL
penicillin. Human embryonic kidney cells (HEK 293) were also obtained from ATCC
and cultured in DMEM nutrient mixture F-12 Ham (Sigma D6421) supplemented with
10% fetal bovine serum, 100 μg/mL streptomycin and 100 U/mL penicillin. All cells
were maintained in a humidiﬁed incubator at 37°C with 5% CO2. For regular
maintenance, cells were sub-cultured when confluency reached approximately 85%.
4.3.2 Cortisol treatment
Cortisol stock solution (100 mM) was prepared in dimethyl sulfoxide (DMSO). Cultured
HTB 126 cells were treated with cortisol at a final concentration of 80 µM for 24 hours
before analysis. Cells mock-treated with DMSO were used as controls.
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4.3.3 NSMase II over-expression
HEK 293 cells were grown in 6-well plates or on 4-chamber slides. Transient transfection
was performed using pCMV-SPORT6 NSMase II expression plasmid (Open Biosystems
6399438) with Lipofectamine LTX reagent (Invitrogen A12621) according to
manufacturer’s recommendations. Transfection was carried out for 36 hours prior to
subsequent analysis. Success of transfection was assessed using immunoblots, as well as
indirect immunofluorescence.
4.3.4 Immunofluorescence
Following cortisol treatment or transfection, cells were fixed with 2% paraformaldehyde
for 1 hour at room temperature. After paraformaldehyde was removed, cells were washed
three times using PBS and blocked with 5% BSA for 1 hour. Then, blocking buffer was
removed and cells were incubated with rabbit anti-NSMase II antibody (1:100; Santa
Cruz Biotechnology sc-67305) for 2 hours. After washing with PBS three times, cells
were further incubated with goat anti-rabbit Alexa 488 (1:500; Invitrogen A-11008) for 1
hour. To visualize the nuclei, cells were stained with either Hoechst 33342 for 5 minutes,
or propidium iodide for 15 minutes. Finally, cells were washed 3 times with PBS and
mounted using Fluoromount G. Images were taken on a Leica microscope using 40X oil
objective.
4.3.5 PFO-D4-GFP_GST expression and purification
The construct PFO-D4-GFP_GST was kindly provided by Dr. Irina Pikuleva from Case
Western Reserve University. This construct was transformed into BL21(DE3) E.coli
(New England BioLabs C2527) using standard heat shock method. Ampicillin at a
concentration of 100 µg/mL was used for selection. When the bacterial culture has
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reached an optical density of approximately 0.6, PFO-D4-GFP_GST expression was
induced by the addition of IPTG to a final concentration of 1 mM. The induced culture
was grown for an additional 5 hours at 37°C before cells were harvested by centrifugation
(4000 g, 30 minutes, 4°C). Following centrifugation, the bacterial cell pellet was
resuspended in lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM PMSF, 1%
Triton X100, 1 mg/mL DNase I and 10 mg/mL lysozyme). Crude lysate was further lysed
by pulse sonication (20 seconds on, 20 seconds off, 10 cycles). Another round of
centrifugation (11300 g, 30 minutes, 4°C) was performed and the clarified lysate was
applied to a glutathione sepharose 4B column pre-equilibrated with wash buffer (50 mM
Tris-HCl pH 8, 150 mM NaCl). After the lysate has passed through the column, 5 column
volumes of wash buffer was used to remove non-bound sample components followed by
elution using wash buffer supplemented with 10 mM GSH. Finally, eluted PFO-D4GFP_GST was concentrated and buffer exchanged into PBS pH 7.4 using Amicon
centrifugal filter (Millipore UFC903008) before storage at -80°C.
4.3.6 PFO-D4-GFP staining
HEK 293 cells were grown on 4-chamber slides. Following transfection, cells were fixed
with 2% paraformaldehyde for 1 hour at room temperature. Fixed cells were then washed
3 times using PBS and stained with PFO-D4-GFP_GST (1 mM) for 30 minutes. To
visualize the nuclei, Hoechst 33342 stain was added for 5 minutes. Finally, cells were
washed 3 times with PBS, mounted using Fluoromount G and imaged on a Leica
microscope with 40X oil objective.
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4.3.7 SMPD3 sub-cloning
Human full length SMPD3, which encodes NSMase II, was sub-cloned into bacterial
expression vector pET28b using Cold Fusion Cloning Kit (MJS BioLynx Inc.
SYMC010A1). The cloning strategy involves direct ligation of PCR amplified gene of
interest to the linearized destination vector. Primers used for PCR were designed
according to manufacturer’s guidelines and contain bases complimentary to the gene of
interest, as well as bases complementary to the linearized destination vector. The
following primers were used for SMPD3 sub-cloning:
Forward 5’ – GTG CCG CGC GGC AGC CAT ATG GTT TTG TAC ACG ACC CCC – 3’
Reverse 5’ – GTG GTG GTG GTG GTG CTC GAG TGC CTC CTC CTC CCC CGA AGA C– 3’

Prior to ligation, destination vector pET28b was linearized by digestion with restriction
enzymes NdeI and XhoI; and both PCR amplified SMPD3 and linearized pET28b were
gel purified (Qiagen 20021). Ligation reaction was performed following manufacturer’s
protocol and the ligated plasmid DNA was transformed directly into chemically
competent DH5 E.coli (New England BioLabs C2987). Colonies were screened using
diagnostic restriction enzyme digest and partial sequencing (Robart’s Research Institute).
4.3.8 NSMase II expression and purification
pET28b_SMPD3 was transformed into BL21(DE3) E.coli (New England BioLabs
C2527). This plasmid encodes full length human NSMase II with two terminal 6XHistidine tags to facilitate purification. A single colony from the transformation plate was
inoculated into 25 mL of 2X YT medium containing 50 µg/mL kanamycin and the
culture was grown overnight at 37°C with shaking. This overnight culture was then used
to inoculate 1L of 2X YT medium containing 50 µg/mL kanamycin and the culture was
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again grown at 37°C until optical density reached approximately 0.6. Protein expression
was induced by the addition of IPTG to a final concentration of 0.4 mM. The induced
culture was grown for an additional 24 hours at room temperature before cells were
harvested by centrifugation (4000 g, 30 minutes, 4°C). Following centrifugation, the
bacterial cell pellet was resuspended in lysis buffer (50 mM Tris-HCl pH 7.5, 300 mM
NaCl, 5 mM MgCl2, 0.2% Triton X100, 1 mM DTT, 1 mM PMSF, 50 µg/mL DNase I
and 100 µg/mL lysozyme). The crude lysate was incubated on ice for 30 minutes and
further lysed by pulse sonication (20 seconds on, 20 seconds off, 30 cycles). Another
round of centrifugation (11300 g, 30 minutes, 4°C) was performed and the clarified lysate
was applied to nickel affinity (Sigma P6611) column pre-equilibrated with lysis buffer.
Nickel affinity purification was performed strictly following manufacturer’s protocol
published by Sigma Aldrich with some modifications in buffer composition. The wash
buffer contains 50 mM Tris-HCl pH 7.5, 300 mM NaCl, 5 mM MgCl2, 0.2% Triton
X100, and 15 mM imidazole while the elution buffer contains 50 mM Tris-HCl pH 7.5,
300 mM NaCl, 5 mM MgCl2, 0.2% Triton X100, and 300 mM imidazole. Eluted protein
was buffer exchanged into storage solution (50 mM Tris-HCl pH 7.5, 5 mM MgCl2 and
0.2% Triton X100) using Amicon centrifugal filter (Millipore UFC903008) before
storage at -80°C.
4.3.9 NSMase Activity assay
NSMase activity was assessed using Amplex Red Sphingomyelinase Assay kit
(Invitrogen A12220) in accordance with manufacturer’s published protocol. In this
fluorescence-based assay, NSMase activity is monitored indirectly using Amplex Red
reagent, which is a fluorogenic probe for H2O2. Briefly, NSMase catalyzed SM
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hydrolysis produces ceramide and phosphorylcholine. Then, phosphorylcholine is acted
upon by alkaline phosphatase and choline oxidase to produce H2O2, which reacts with
Amplex Red in the presence of horseradish peroxidase to generate a highly fluorescent
end product.
4.3.10 Mass spectrometry
Purified NSMase II (1 mg/mL) was treated with 0.5 mM GSNO for 30 minutes in the
dark. Enzyme mock-treated with PBS was used as the control. Following GSNO
treatment, free –SH groups in NSMase II were labeled using 20 mM iodoacetamide (2
hours, room temperature, in the dark). Excess iodoacetamide was removed by passing the
samples through desalting columns (Fisher Scientific 89882). Then, 10 mM sinapinic
acid was used to reduce S-nitrosated thiols (1 hour, room temperature), followed by 20
mM N-ethylmaleimide treatment to label previously S-nitrosated thiols (50°C, 30
minutes). After labeling, excess N-ethylmaleimide was removed and samples were
buffered exchanged into 50 mM ammonium bicarbonate (pH8.0) using desalting
columns. Finally, protein samples were digested with trypsin (Promega V511A)
overnight at 37°C (1:20 trypsin to protein ratio). C18 Zip Tips (Millipore ZTC18S096)
were used to clean up the tryptic peptides before MS analysis.
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4.4 Results and Discussion
4.4.1 Effect of cortisol treatment on NSMase II expression and activity
NSMase II catalyzed ceramide generation is involved in cellular stress response.
Stressors such as hydrogen peroxide can selectively up-regulate the expression or activity
of NSMase II; concomitant increase in ceramide levels then mediates the appropriate
stress response (e.g., cell cycle arrest, apoptosis) [228]. In this section, cortisol exposure
was used as the stressor and its effect on endogenous NSMase II expression and activity
was investigated. Triple negative breast cancer cells (HTB 126) were exposed to 80 µM
cortisol for 24 hours. Following treatment, cell viability was assessed using Trypan Blue.
Results show cortisol exposure does not negatively affect viability. Both control and
treated cells exhibit similar viability at approximately 95% (Figure 4.4.1-1 A). NSMaseII
expression level and activity were determined using immunofluorescence and Amplex
Red enzyme-coupled assay, respectively. In both cases, no significant difference was
observed between DMSO-treated control cells and cortisol-treated cells (Figure 4.4.1-1
B-D). However, cortisol-treated cells are larger in size than their control counterparts
(Figure 4.4.1-1 B). Although the underlying mechanism has not yet been determined, it
is possible that cortisol could play a role in promoting cell growth or inhibiting cell
division.
To explore the reason for lack of NSMase II activation in response to cortisol, the
following factor should be considered:
1. HTB126 is a triple negative breast cancer cell line. Its basal level of NSMase II
expression and activity needs to be carefully evaluated. For this project, Amplex Red
assay kit was used to estimate NSMase II activity. This method is indirect and measures
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enzyme coupled hydrogen peroxide generation. Although this assay works well with
purified NSMase II in vitro, it may not be suitable for complex cellular lysate samples
since enzymes/molecules within the lysate could affect hydrogen peroxide levels.
Measurement of cellular ceramide levels will complement our NSMase II activity results.
2. Acute stress and chronic stress may elicit different responses. Varying the length of
cortisol exposure will offer insight in this area.
3. In literature, NSMase II was almost always over-expressed before cells were exposed
to stimuli/stressor; whereas we looked at endogenous NSMase II. Different experiment
methods will affect results obtained.
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Figure 4.4.1-1 Effect of cortisol treatment on NSMase II expression and activity
HTB 126 cells were treated with 80 µM cortisol for 24 hours. (A) Viability was assessed
using trypan blue exclusion assay. Percent viable is shown as mean ± SD (n=4). (B) After
cortisol treatment, cells were fixed using 2% paraformaldehyde, stained with antiNSMase II antibody, followed by Alexa 488 conjugated secondary antibody. Nuclei were
visualized using propidium iodide. 3 representative images were shown from 3
independent experiments. Scale bar = 25 µm. (C) Fluorescence from ~50 cells were
quantified using ImageJ as integrated density. Cumulative results were shown as % of
control. Error bars represent SD. (D) NSMase activity from cell lysate was estimated
using the Amplex Red activity assay kit. Results are shown as % of control. Error bars
represent SD.
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4.4.2 NSMase II over-expression is associated with decreases in plasma
membrane cholesterol content
Within the plasma membrane, SM preferentially associates with cholesterol to form
ordered microdomains [240] and evidence exist for the coordinated regulation of SM and
cholesterol levels [233]. To determine whether plasma membrane cholesterol levels can
be indirectly regulated by NSMase II activity, transient transfection was performed to
over-express untagged NSMase II in HEK 293 cells. Transfection success was confirmed
using immunoblotting (Figure 4.4.2-1 A). Activity assay was performed and more than
2-fold increase in activity was observed following transfection (Figure 4.4.2-1 B),
demonstrating that over-expressed NSMase II is active. PFO-D4-GFP_GST was used to
label plasma membrane cholesterol and imaging results indicated an inverse relationship
between NSMase II expression/activity and plasma membrane cholesterol content
(Figure 4.4.2-2). This demonstrates modulation of NSMase II activity is accompanied by
alterations in plasma membrane cholesterol level; which is suggestive that in addition to
ceramide generation, NSMase II may also elicit physiological responses by affecting lipid
raft formation.
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Figure 4.4.2-1 Over-expression of NSMase II is correlated with increased activity
HEK 293 cells were transiently transfected to over-express NSMase II. (A) 36 hours after
transfection, cells were harvested and lysed using non-denaturing lysis buffer. Protein
concentrations were determined for each sample and equal amounts were run on SDSPAGE. Following separation, proteins were transferred to PVDF membrane and blotted
for NSMase II. (B) NSMase activity from cell lysate was estimated using Amplex Red
NSMase activity assay kit. Results are shown as % of control. Error bars represent SD.
*Statistically different from control (p < 0.05).
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Figure 4.4.2-2 NSMase II over-expression is correlated with decreased plasma
membrane cholesterol level
HEK 293 cells were plated on 4 chamber slides and transiently transfected to overexpress NSMase II. (A) 36 hours after transfection, cells were fixed using 2%
paraformaldehyde, stained with anti-NSMase II antibody, followed by Alexa 488
conjugated secondary antibody. Nuclei were visualized using Hoechst 33342 stain. 3
representative images were shown from 3 independent experiments. Scale bar = 25 µm.
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(B) Fluorescence from ~50 cells were quantified using ImageJ as integrated density.
Cumulative results were shown as % of control. Error bars represent SD. (C) Cells were
fixed using 2% paraformaldehyde and labeled with the plasma membrane cholesterol
probe PFO-D4-GFP_GST. Nuclei were visualized using Hoechst 33342 stain. 3
representative images were shown from 3 independent experiments. Scale bar = 25 µm.
(B) Fluorescence from ~50 cells were quantified using ImageJ as integrated density.
Cumulative results were shown as % of control. Error bars represent SD. *Statistically
different from control (p < 0.05).
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4.4.3 S-nitrosation mediated down-regulation of NSMase II activity
Exposure to cigarette smoke and hydrogen peroxide has been shown to lead to NSMase II
activation, which augments ceramide mediated apoptosis in bronchial epithelial cells
[160]. Interestingly, when we treated HTB 126 cells with hydrogen peroxide, NSMase II
activity decreased by approximately 40% and cell viability was not negatively affected
(Figure 4.4.3-1). This led us to speculate whether NSMase II activity is selectively
down-regulated in cancer cells in order to evade ceramide induced apoptosis. Since
human NSMase II is a redox-sensitive enzyme with a total of 23 cysteine residues, Snitrosation became the candidate modification under investigation. Currently, reactivity
of these cysteine residues, as well as their susceptibility towards modification, are not
fully understood. We purified recombinant NSMase II from bacteria and our enzyme
preparation is catalytically functional (Figure 4.4.3-2 A). Incubation with GSNO
decreases NSMase II activity in a concentration dependent manner (Figure 4.4.3-2 B),
suggesting potential regulation of enzyme activity through protein S-nitrosation.
Numerous attempts were made to identify candidate S-nitrosation sites using mass
spectrometry. This has proven to be challenging due to low sequence coverage and low
signal intensity. Very few peptides were detected and none of them contain cysteine
residues (Table 4.4.3). This might be due to inherent properties of membrane proteins
and peptide enrichment is likely needed in order to achieve better sequence coverage.
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Figure 4.4.3-1 Effect of hydrogen peroxide treatment on HTB 126 cells
HTB 126 cells were treated with hydrogen peroxide in complete cell culture medium for
30 minuts. (A) Viability was assessed using Trypan Blue. (B) Following treatment,
culture medium was removed and cells were washed 3 times with DPBS. Lysates were
prepared by homogenization and total protein concentration was determined using
Bradford reagent. NSMase II activity from cellular lysates (protein concentrations were
equalized) was assayed using Amplex Red assay kit. Error bars represent SD (n=3).
*statistically different from control.
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Figure 4.4.3-2 In vitro GSNO treatment attenuates NSMase II activity
Recombinant NSMase II was purified from E.coli. (A) NSMase II activity from purified
enzyme preparation was assayed using Amplex Red assay kit. (B) Purified NSMase II
was treated with various concentrations of GSNO for 30 minutes. Enzyme activity was
then assessed using Amplex Red assay kit. Error bars represent SD.
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Figure 4.4.3-3 MALDI-MS spectrum of NSMase II tryptic digest
Purified NSMase II is treated with 0.5 mM GSNO and differentially labeled with
iodoacetamide and N-ethylmaleimide. Sample is digested with trypsin and analyzed using
Applied Biosystems Voyager DE-Pro Mass Spectrometer. Spectra peaks were manually
compared to theoretical digest masses predicted by UCSF Protein Prospector.

Table 4.4.3 NSMase II peptides identified by MALDI-MS
Theoretical Mass
(m/z)
954.5156
954.5479

Observed Mass
(m/z)
954.5255

Peptide Sequence

1055.5408

1055.4794

(R)EYLAFPTSK(S)

1074.5538

1074.4829

(K)VLESEEGRR(E)

1176.6120

1176.4709

(R)VNNLFNTQAR(A)

1214.6124

1214.4341

(K)VQVGSTPQDQR(I)

1340.7096

1340.4207

(R)LAASFIPTTYEK(R)

1558.7761

1558.3383

(K)LEQQHSLFTHYR(D)

2161.0268

2160.0500

(R)IGGEEGGRPPEADDPVPGGQAR(N)

2297.0137

2296.9139

(R)GQTPNHNQQDGDSGSLGSPSASR(E)

2997.4800

2996.7330

(K)IYIDSPTNTSISAASFSSLVSPQGGDGVAR(A)

(R)RPYIYSR(L)
(R)NGAARPQIK(I)
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4.5 Conclusion
Cortisol exposure at a concentration of 80 µM led to increases in cell size. However,
NSMase II expression and activity were not affected. When looking at the relationship
between NSMase II and plasma membrane cholesterol, it was observed that increased
NSMase II activity is correlated with decreased cholesterol. This suggests NSMase II
activity may contribute to the regulation of lipid raft signaling events. In addition, we
presented evidence that S-nitrosation is potentially involved in the down-regulation of
NSMase II activity. Further studies will need to be performed to identify specific residues
involved.
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CHAPTER 5
General Conclusion
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Protein S-nitrosation is the covalent attachment of NO derived nitroso group to reactive
cysteine thiols. This reversible post-translational modification affects many aspects of
protein function, such as activity, localization and stability. In the cellular environment,
S-nitrosated proteins often exist in equilibrium with GSNO via transnitrosation. As a
result, enzymes with GSNO metabolizing activity can indirectly drive protein
denitrosation. Multiple enzyme systems have been shown to metabolize GSNO. Of these
enzymes, GSNOR is the most efficient at removing the NO equivalents stored in GSNO.
In addition, aberrant GSNOR activity is implicated in a large number of human diseases.
GSNOR inhibition represents a relatively recent therapeutic approach and the evaluation
of small molecule inhibitors is an active area of research. Conventionally, GSNOR
activity is assayed by looking at absorbance decreases at 340 nm, which corresponds to
NADH and GSNO consumption. While this method is easy to use, its application is
limited to purified enzyme in vitro. In chapter 2, we reported the synthesis and
characterization of OAbz-GSNO, a fluorogenic substrate for GSNOR. The fluorescence
of OAbz-GSNO is enhanced upon reduction of its –SNO moiety; and the rate of
fluorescence increase is correlated with GSNOR activity. This substrate is membrane
permeable and can be used to monitor endogenous GSNOR activity in live cells. Overall,
OAbz-GSNO is the first compound to be reported which can be used to measure GSNOR
activity, both in vitro and in live cells. This substrate represents an additional tool
researchers could use to assess the activity of GSNOR.
It is well-established that GSNOR plays an important role in maintaining SNO
homeostasis. However, regulation of its activity remains poorly understood. Chapter 3
focuses on the identification of potential post-translational mechanisms involved in the
regulation of GSNOR activity. Site-directed mutagenesis and chemical acetylation
experiments provided evidence that acetylation of Lys101, which is adjacent to the zinc
118

finger motif, may negatively regulate GSNOR activity. Through kinetic and
computational studies, we also identified a putative allosteric GSNO binding site. Results
suggest GSNO binding to this allosteric site may enhance GSNOR activity. Our model of
substrate activation allows GSNOR to exhibit enhanced activity when GSNO is present,
effectively returning the system to homeostasis.
NSMase II catalyzes the hydrolysis of sphingomyelin to generate bioactive
ceramide, a second messenger molecule capable of mediating a variety of cellular events.
Activation of NSMase II is an important mechanism of cellular stress response. In
chapter 4, we exposed cultured breast cancer cells to cortisol and observed that this
treatment did not have any effect on NSMase II expression/activity. Interestingly,
cortisol-treated cells grew to be much larger in size than their control counterparts. The
underlying mechanism has yet to be determined. NSMase II over-expression was
correlated with decreased plasma membrane cholesterol levels. Since cholesterol is an
important component in the formation of lipid rafts, this finding carries the implication
that induction of NSMase II not only generates ceramide, but could also affect additional
signaling pathways mediated through lipid rafts. In vitro treatment with GSNO attenuates
NSMase II activity, suggesting that protein S-nitrosation may be one of the modifications
involved in the regulation of NSMase II activity.
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Appendix A – NMR Characterization

Figure A.1 Correlation spectroscopy (COSY) of OAbz-GSNO
Pooled OAbz-GSNO was lyophilized and re-dissolved in minimum volume D2O.
Spectrum was collected on a Bruker 500 MHz Avance III spectrometer using a BBFO
probe. This COSY spectrum was used to assign 1H NMR peaks for OAbz-GSNO.
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Appendix B – Recombinant Protein Sequence

MGSSHHHHHH SSGLVPRGSH MANEVIKCKA AVAWEAGKPL SIEEIEVAPP
KAHEVRIKII ATAVCHTDAY TLSGADPEGC FPVILGHEGA GIVESVGEGV
TKLKAGDTVI PLYIPQCGEC KFCLNPKTNL CQKIRVTQGK GLMPDGTSRF
TCKGKTILHY MGTSTFSEYT VVADISVAKI DPLAPLDKVC LLGCGISTGY
GAAVNTAKLE PGSVCAVFGL GGVGLAVIMG CKVAGASRII GVDINKDKFA
RAKEFGATEC INPQDFSKPI QEVLIEMTDG GVDYSFECIG NVKVMRAALE
ACHKGWGVSV VVGVAASGEE IATRPFQLVT GRTWKGTAFG GWKSVESVPK
LVSEYMSKKI KVDEFVTHNL SFDEINKAFE LMHSGKSIRT VVKILEHHHH
HH*
Figure B.1 Recombinant GSNOR protein sequence
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MGSSHHHHHH SSGLVPRGSH MVLYTTPFPN SCLSALHCVS WALIFPCYWL
VDRLAASFIP TTYEKRQRAD DPCCLQLLCT ALFTPIYLAL LVASLPFAFL
GFLFWSPLQS ARRPYIYSRL EDKGLAGGAA LLSEWKGTGP GKSFCFATAN
VCLLPDSLAR VNNLFNTQAR AKEIGQRIRN GAARPQIKIY IDSPTNTSIS
AASFSSLVSP QGGDGVARAV PGSIKRTASV EYKGDGGRHP GDEAANGPAS
GDPVDSSSPE DACIVRIGGE EGGRPPEADD PVPGGQARNG AGGGPRGQTP
NHNQQDGDSG SLGSPSASRE SLVKGRAGPD TSASGEPGAN SKLLYKASVV
KKAAARRRRH PDEAFDHEVS AFFPANLDFL CLQEVFDKRA ATKLKEQLHG
YFEYILYDVG VYGCQGCCSF KCLNSGLLFA SRYPIMDVAY HCYPNKCNDD
ALASKGALFL KVQVGSTPQD QRIVGYIACT HLHAPQEDSA IRCGQLDLLQ
DWLADFRKST SSSSAANPEE LVAFDVVCGD FNFDNCSSDD KLEQQHSLFT
HYRDPCRLGP GEEKPWAIGT LLDTNGLYDE DVCTPDNLQK VLESEEGRRE
YLAFPTSKSS GQKGRKELLK GNGRRIDYML HAEEGLCPDW KAEVEEFSFI
TQLSGLTDHL PVAMRLMVSS GEEEAHHHHH H*

Figure B.2 Recombinant NSMase II protein sequence
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Appendix C – Protein Purification Gels

Figure C.1 GSNOR and GSNOR K101A protein purification gels
Following Nickel affinity chromatography and buffer exchange, purified proteins were
analyzed on 10% SDS-PAGE gels under reducing conditions. Protein bands were
visualized using Coomassie Brilliant Blue.
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Figure C.2 GSNOR K101Q protein purification gel
Following Nickel affinity chromatography and buffer exchange, purified GSNOR K101Q
was analyzed on 10% SDS-PAGE gel under reducing conditions. Protein bands were
visualized using Coomassie Brilliant Blue.
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Figure C.3 NSMase II protein purification gel
Following Nickel affinity chromatography and buffer exchange, purified NSMase II was
analyzed on 10% SDS-PAGE gel under reducing conditions. Protein bands were
visualized using Coomassie Brilliant Blue.
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